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ABSTRACT

Changes in cognitive status occur with aging and significant attention has been placed on
developing interventions to possibly delay cognitive decline and identifying risk factors that
exacerbate cognitive deficits. One issue that arises when studying interventions is that they do
not always effectively translate from animal models to human subjects. When testing potentially
modifiable risk factors related to cognitive impairment, more sensitive metrics could help in
identifying targets for intervention at earlier time-points. Therefore, the aims of the current
dissertation were twofold. The first study examined the ability to translate between species using
a common behavioral paradigm, the Morris water maze (MWM). The second study evaluated
human MWM performance and commonly used neuropsychological test performance in relation
to a marker of glucose regulation, HbA1c.
The first study tested translation between rats and humans using the MWM paradigm.
Using secondary data sources from a study of nutrition, inflammation, and aging among rats and
the Czech Brain Aging Study among humans, differences in average performance and across
trial learning were examined between young (3 months; n=10) and aged (20 months; n=13) rats
as well age young-old (age 53-70; n=47) and old-old (age 71-85; n=30) human subjects. The
cumulative distance was measured in rats and distance error to the hidden goal was measured in
human subjects. Results indicated that age-related deficits in performance are greater in
magnitude for rats than human subjects. Further, the across trial learning data is more sensitive to
change in performance than average performance metrics. Across learning trials indicated poorer
vii

performance for aged rats than young rats. Significant effects of age were also observed for
human subjects using with the allocentric and egocentric subtests.
The second study examined the influence of a measure of glucose regulation (HbA1c) on
commonly used neuropsychological tests and a test of spatial navigation abilities among human
subjects. Participants classified as cognitively normal, subjective cognitive decline, amnestic
mild cognitive impairment (aMCI), and Alzheimer’s disease (AD) were evaluated on verbal
memory, nonverbal memory, working memory, visuospatial skills, and executive function in
addition to the virtual and real space versions of a human MWM paradigm. A total of 116
participants were included in the complete data sample and 133 participants were included in the
multiple imputation sample. Results indicated that HbA1c influenced executive function but not
any other measures of cognition. Higher HbA1c levels were associated with poorer performance.
A significant interaction was observed between cognitive status and HbA1c. Those with
cognitive impairment and higher HbA1c levels had poorer executive function performance. This
effect, however, was not observed with the imputation sample.
Results of the first study indicated that the MWM paradigm serves as a good tool to
assess translation between rats and human subjects. This would be helpful in examining
interventions designed to improve normal age-related changes in cognition. It is important to
note, however, that the differences observed among animals tend to be greater than human
subjects. Therefore, the margin of improvement may be greater following treatment with studies
utilizing animals rather than human subjects. The second study indicated that glucose levels may
have an impact on cognitive abilities, particularly those related to executive function. Targeting
blood glucose levels may be one effective way to keep executive function abilities more intact
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with age. Taken together, these studies will better inform future work related to delaying
cognitive decline among older adults.
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CHAPTER ONE:
INTRODUCTION

The number of adults over the age of 65 in the United States is continuing to grow and
will account for approximately one-fifth of the population by the year 2050 (Ortman, Velkoff, &
Hogan, 2014). As the aging population continues to increase, issues associated with cognitive
status are of interest. This is particularly so as an estimated 13.8 million individuals will be
diagnosed with Alzheimer’s disease (AD) by 2050 (Hebert, Weuve, Scherr, & Evans, 2013).
Poorer performance in tests of memory, visuospatial abilities, speed of processing, and executive
function have been observed with increasing age (Goh, An, & Resnick, 2012; Salthouse, 2009;
Schaie, 2005; Singh-Manoux et al., 2012). Therefore, differentiating between normal changes
observed with cognitive aging as compared to cognitive impairment has gained substantial
interest. This relationship has been tested not only among human subjects, but also in animal
models.
Animal models including nematodes, fruit flies, mice, rats, and non-human primates have
been used to gain a better understanding of the biological, psychological, and social phenomenon
present in humans. When studying aging, rats and mice have proven to be useful models due to a
shorter lifespan as compared to their human counterparts and the ability to model long-term
changes over relatively short follow-up periods (Mitchell, Scheibye-Knudsen, Longo, & de
Cabo, 2015). Further, animal models such as mice have been useful in studying diseases related
to aging. For instance, mice genetically altered to display the pathology and behavioral deficits
1

associated with AD have been used to test potential treatments for this condition. Finally, animal
models are reared in a controlled environment which may reduce some confounds observed
among human subjects.
A commonly used paradigm for studying learning and memory in mice and rats is the
Morris water maze (MWM). Deficits in performance on the MWM have been observed for both
aged mice and rats (Forster et al., 1996; Lindner, 1997; Shukitt-Hale, Mouzakis, & Joseph,
1998). Translating this behavioral test for use in human subjects has also been of interest (Hort et
al., 2007; Kalová, Vlcek, Jarolimová, & Bures, 2005; Moffat & Resnick, 2002). Using a similar
paradigm as the MWM in rats and mice, differences in navigation abilities between young and
aged adults have been observed. The relationship between spatial navigation performance and
cognitive status among older adults has also been studied. Results have suggested that
participants with mild cognitive impairment (MCI) and AD show substantial deficits in spatial
navigation performance (Hort et al., 2007; Laczó et al., 2010) and that human MWM paradigms
may be more sensitive to detecting subtle deficits in cognitive abilities (Laczó et al., 2011).
This task may be more sensitive to individual difference predictors of cognitive
performance as well. One such category of variables are biomarkers. The relationship between
measures of glucose control and cognition has gained attention, as several studies have suggested
the detrimental effects of high glucose levels among those with and without diabetes (Crane et
al., 2013; Dahle, Jacobs, & Raz, 2009; Seetharaman et al., 2015). The human analog of the
MWM may be better able to detect individual differences in cognitive abilities that are related to
biological functioning, such as glucose control, than other measures of cognition.
With this considered, the proposed research will focus upon a commonly used behavioral
test which assesses memory and spatial navigation abilities, the MWM. This research will follow
2

two phases. The first phase will focus upon the ability to translate data between rats and humans.
Comparisons within species as well as between species will be made during this portion of the
study. This will include evaluating performance on the MWM for young and aged rats in
comparison to aged humans. Effect sizes will be calculated to test the magnitude of differences
between groups.
The second phase of the study will focus upon the human paradigm with additional
biomarker analyses. The influence of HbA1c, a measure of glucoregulation, on MWM
performance will be assessed among older adults with normal cognitive functioning, subjective
cognitive decline, MCI, and AD. Further, the impact of HbA1c on cognitive abilities measured
by the MWM test and other commonly used neuropsychological tests will be compared. Taken
together, these studies will provide further evidence for or against the use of MWM paradigm
across species as well as a greater understanding of the relationship between glucoregulation and
cognitive functioning among human subjects.

3

CHAPTER TWO:
LITERATURE REVIEW

The literature review will address several key issues relevant to translational research.
First, the importance of animal research in informing studies among human subjects will be
discussed as well as concerns regarding this type of research. Next, the use of the MWM
paradigm will be examined as a potential model for learning, memory, and spatial navigation.
This will first be explored among animals, specifically rats. The use of a human analog of the
MWM will also be described and compared across species. The second portion of the literature
review will focus upon the use of biomarker data among humans in relation to cognition. A brief
discussion of the biomarkers related to spatial navigation abilities and future directions for this
area of study will also be presented.
Translational Research
Importance of Animal Studies
Animal studies have long been used to better inform research on human disorders. From
nematodes to fruit flies and mice, animal research has allowed for the study of normal aging
processes as well as pathological states (Mitchell et al., 2015). This includes testing mechanisms
of action that may drive the aging process as well as evaluating potential interventions to slow
aging and the associated cellular and cognitive changes (Bishop, Lu, & Yankner, 2010; MartinMontalvo et al., 2013; van Praag, Shubert, Zhao, & Gage, 2005). There has also been interest in
evaluating this relationship among animal models of diseases that are more likely to occur with
4

increasing age (e.g. Parkinson’s disease, Alzheimer’s disease). Animal models may be an
advantageous starting point for researchers as they have a shorter lifespan, have a controlled
environment in which they are reared, have the ability to reproduce more rapidly than humans,
and are more cost effective than human subjects (Mitchell et al., 2015; Roberson et al., 2012).
Caveats of Translational Research and Translation to Human Subjects
When translating research between rodent models and humans, researchers must be
cognizant of a number of issues. For instance, when considering measures of cognitive status and
aging, it is important to examine multiple domains of cognitive function (Alexander et al., 2012).
Tests of memory, particularly those related to associative, recognition, spatial, working and
contextual abilities, as well as executive function and visual perception may be advantageous
when comparing rodents to humans (Roberson et al., 2012). Although there are cognitive or
behavioral tests that are similar among human and rodent models, these tests may not precisely
map on to one another (Alexander et al., 2012).
Further, species specific concerns may lead to difficulty with translation. Housing
environment, handling procedures, testing time, and testing order can all impact the results of
behavioral data when using rodent models (Roberson et al., 2012). Human studies of cognitive
processes have issues that may influence performance as well, which include greater
heterogeneity between test subjects as compared to rodent models and dependence on language
abilities for many cognitive tests (Roberson et al., 2012). Having animal models that
appropriately represent human pathology must also be considered, particularly with studies
focused upon interventions or novel therapeutic agents (McGonigle & Ruggeri, 2014). This issue
has become apparent in mouse models of AD, many of which represent familial forms of the
disease rather than the more common sporadic condition (McGonigle & Ruggeri, 2014).
5

Mishra and Gazzaley (2016) suggest that cross-species studies, where similar
methodologies are tested between animals and human subjects, may be helpful in identifying
common correlates in cognitive function and associated neural mechanisms. One disadvantage to
this type of study, however, is in examining the neural mechanisms underlying cognitive
abilities. Cellular level changes are more universally studied among animals whereas regional
brain functioning is more so studied among humans (Mishra & Gazzaley, 2016). While this may
pose a challenge, it should not deter researchers from adopting this methodology.
The Morris Water Maze (MWM)
The Morris water maze (MWM) task was first developed for use among rats to test
learning, memory, and spatial navigation abilities (R. G. M. Morris, 1981, 1984). The objective
of the MWM task is to locate a hidden platform in a circular pool of water using distal visual
cues. In this experiment, rats are released from one of four locations (e.g. north, east, south,
west) and must locate a platform hidden under the opaque water of the pool (R. G. M. Morris,
1981). The platform may remain in the same quadrant across trials or switch between trials. The
amount of time taken and the length of the route to locate the platform as well as the swim
pattern and speed are measured for each trial. Following hidden platform trials across multiple
days, the platform is then removed to complete the probe trials. The rat is given a period of time
(typically 60 seconds) to freely swim in the pool and the time spent in the goal quadrant and
number of times crossing the location of the previous platform are measured (R. G. M. Morris,
1981). Since its original conceptualization, differing protocols have been used to test learning,
memory, and spatial orientation (Vorhees & Williams, 2006).
While the MWM was developed among animals, it has also been utilized among human
subjects indicating the utility of this measure in translational behavioral research. For instance, a
6

recent study has compared the use of a MWM paradigm between human amyloid precursor
protein (hAPP) mice displaying early cognitive impairment and human subjects with MCI
(Possin et al., 2016). During training with a visible platform, the hAPP mice displayed deficits as
compared to their non-transgenic counterparts. This relationship was not observed during the
visible target training with humans (Possin et al., 2016). However, poorer performance was
observed for both hAPP mice and MCI participants as compared to the control groups for the
hidden goal or hidden target test as well as proximity to the target location for the probe trial
(Possin et al., 2016). These results indicate that the use of MWM paradigms across species may
be of benefit, particularly when the methods and cognitive status of study subjects are matched
across studies. A further evaluation of MWM performance by species will follow.
Aging Rats
Age related deficits in MWM performance has been observed among rats. There appears
to be a linear relationship between the ability to locate the hidden platform and age, with older
rats traveling a greater distance (Lindner, 1997). While older animals have the capacity to learn
the task, age-related deficits may be present around 18 months of age depending on the strain of
rat (Shukitt-Hale et al., 1998). This age in rats (18 months) would be equivalent to a human
subject in his or her 40s (Quinn, 2005). However, individual differences in MWM performance
within each age group are quite variable, indicating that age is not the only predictor of
performance on this task (Lindner, 1997; Shukitt-Hale et al., 1998).
The relationship between aging, spatial navigation abilities, reference memory and
episodic memory has more recently been examined in a cohort of rats age five to 22 months
(Guidi, Kumar, Rani, & Foster, 2014). When assessing spatial navigation performance, young
rats swam a significantly shorter distance to locate the hidden platform than their middle-aged
7

and older counterparts. Following the traditional test of spatial navigation abilities, rats were then
either trained an additional 7 days on the navigation task or were given a one day training task
with the platform remaining in the same place (reference memory group) or with the platform
relocated in relation to distal cues (episodic memory group). Following this additional training,
age differences emerged for animals in the episodic memory group more so than the reference
memory group. Middle aged and old animals in the episodic memory group had poorer
performance than young animals whereas this relationship was only observed among the old
animals in the reference memory group (Guidi et al., 2014). This suggests that episodic memory
may be more negatively impacted into older age than reference memory for MWM performance.
The MWW has also been commonly used in rodent studies to test the effectiveness of
various interventions (e.g. pharmacological agents, nutritional supplements, environmental
enrichment). Following administration of the intervention, animals are tested on the MWM to
determine if performance is better for the animals in the experimental group as compared to the
control group or if performance improves across trials. Shorter distance to locate the platform or
decreased latency to reach the platform is indicative of improvements in learning and memory
abilities. For instance, both aged rats and AD mouse models given nutritional supplement
interventions have shown improved performance in spatial navigation tasks (Acosta et al., 2010;
Fernández-Fernández et al., 2012; Matchynski et al., 2013; Thangthaeng, Miller, Gomes, &
Shukitt-Hale, 2015).
Classifying Human Subjects by Cognitive Status
Before discussing spatial navigation among human subjects, it is important to provide a
brief overview regarding the classification of cognitive status. While some changes in cognitive
status are anticipated with aging, deficits beyond these expectations result in individuals being
8

classified as having cognitive impairment or dementia. Of particularly interest among older
adults are the conditions known as subjective cognitive decline (SCD), mild cognitive
impairment (MCI), and Alzheimer’s disease (AD).
Normal Cognitive Functioning
As individuals age, many changes in cognitive status are observed. Numerous studies
have been conducted examining changes in cognitive function with aging (Salthouse, 2009;
Schaie, 2005; Singh-Manoux et al., 2012). In general, among older adults verbal abilities are
thought to be relatively well preserved with age whereas memory, executive function, speed of
processing, and visuospatial abilities tend to decline with age (Schaie, 2005). However, the age
at which these changes begin has been somewhat contested and may be dependent upon the
design of the study (cross-sectional versus longitudinal) as well as the outcome of interest.
Longitudinal studies suggest that age related changes in performance for reasoning, spatial
orientation, verbal memory, episodic memory, and perceptual speed begin when reaching the
sixth decade of life (Rönnlund, Nyberg, Bäckman, & Nilsson, 2005; Schaie, 2005). Crosssectional studies suggest that deficits in cognitive performance begins much earlier, perhaps
when individuals are in their late 20s (Salthouse, 2009). In either case, there has been evidence
for age-related differences in cognitive abilities. When these changes become greater than what
is typically expected for age, however, concerns arise.
Subjective Cognitive Decline (SCD)
The concept of subjective cognitive decline (SCD) has been used to describe selfreported changes in cognition that are beyond age-related normal changes. This categorization of
cognitive status would be representative of an intermediary stage between normal cognitive
function and MCI. According to the Subjective Cognitive Decline Initiative Working Group
9

(Jessen et al., 2014), SCD due to AD is classified by several features. This includes having a
noticeable change in cognitive abilities as observed by the individual or an informant, but having
typical or average performance on neuropsychological tests (Jessen et al., 2014). Additionally,
the individual would not be classified as having SCD if another cognitive diagnosis was present
(MCI, AD) or if the change in cognitive status is due to another acute condition or disorder.
Mild Cognitive Impairment (MCI)
MCI has been conceptualized as a transitional stage in cognitive status between normal
cognitive aging and dementia (Albert et al., 2011; Petersen, 2004). Moreover, persons with MCI
exhibit a greater rate of conversion to dementia, being at approximately 3% to 15% per year for
individuals diagnosed with MCI (Farias, Mungas, Reed, Harvey, & DeCarli, 2009). The
following conditions must be met for MCI diagnosis: subjective cognitive complaint by the
individual or informant, objective cognitive impairment as measured by neuropsychological
testing across one or more cognitive domains (typically 1 to 1.5 SD below the age and education
normative mean), relatively intact activities of daily living performance, and absence of dementia
(Albert et al., 2011; Petersen, 2004; Petersen et al., 2014).
The diagnosis of MCI can be further divided into subdomains such as amnestic and nonamnestic forms. Amnestic MCI (aMCI) is classified based on impairments in memory skills
whereas non-amnestic (naMCI) includes impairments in other domains of cognitive functioning
including language, executive function, and visuospatial abilities (Petersen, 2004). It is important
to note that aMCI is more prevalent than naMCI (Roberts et al., 2012). For instance, participants
in the Mayo Clinic Study of Aging were twice as likely to be diagnosed with aMCI as compared
to naMCI (Petersen, 2009). Individuals with MCI can additionally be defined as having deficits
in only one aspect of cognition (single-domain) or several aspects of cognition (multiple domain;
10

Petersen, 2004). Most often deficits in executive function and memory are observed (Albert,
Blacker, Moss, Tanzi, & McArdle, 2007; Goh et al., 2012).
While MCI may be a useful classification for cognitive status that is beyond normal
changes with age, it is not without shortcomings. Some believe that MCI should not be classified
as its own condition, but rather as an early stage of AD (J. C. Morris, 2012). Further, issues with
diagnostic scales to classifying MCI, selection of the study participants, selection of the
cognitively normal comparison group, age of the participants being studied, design of the study
(retrospective versus prospective), duration of follow-up, source of recruitment (clinical versus
community based), and blindness to prior cognitive diagnoses may lead to heterogeneity within
this classification (Bischkopf, Busse, & Angermeyer, 2002; Farias et al., 2009; Petersen, 2004;
Petersen et al., 2014).
Alzheimer’s disease (AD)
AD is a neurodegenerative disorder characterized by alterations in learning, memory,
language, and executive function and changes in behavior due in part to amyloid beta (Aβ)
plaques and neurofibrillary tangles (Jack et al., 2010; McKhann et al., 2011). By the year 2020, it
is estimated that 5.8 million adults over the age of 65 in the United States will be diagnosed with
AD (Hebert et al., 2013). To classify individuals with this condition, the National Institute on
Aging Alzheimer’s Workgroup has suggested a set of diagnostic criteria for probable AD
dementia (McKhann et al., 2011). This includes: impairment in daily functioning onset of
symptoms over time, decline in cognitive abilities as reported by the individual or an informant,
cognitive deficits in memory, language, visuospatial abilities, and/or executive function, and the
absence of another neurological condition or psychiatric disorder (McKhann et al., 2011).
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During the progression from normal cognitive status to AD, it appears that pathology at
the biological level precedes cognitive symptoms in a stepwise manner (Jack et al., 2010;
Sperling et al., 2011). Accumulation of Aβ typically starts this cascade and is followed by
alterations in brain activity as measured by functional magnetic resonance imaging (fMRI). The
next stage of progression involves the accumulation of tau pathology, which results in neuronal
injury or death. The final stage prior to the onset of cognitive symptoms are changes in brain
volume, particularly the medical temporal lobe, as measured by MRI (Jack et al., 2010; Sperling
et al., 2011).
Spatial Navigation
Spatial navigation abilities have been studied among humans in addition to rodent models
(Daugherty & Raz, 2016; deIpolyi, Rankin, Mucke, Miller, & Gorno-Tempini, 2007; Hort et al.,
2007; Laczó et al., 2012; Moffat & Resnick, 2002). There are two types of navigation strategies
commonly studied among humans, which includes egocentric and allocentric abilities.
Egocentric navigation relies on the start position of the subject and his or her position in space
whereas allocentric navigation relies on the use of distal visual cues (Burgess, Maguire, &
O'Keefe, 2002). While navigation can be subdivided into allocentric and egocentric strategies,
these strategies can also be utilized in combination with one another (Burgess, 2006).
There has been support for specific brain region involvement related to particular
functions of spatial navigation. The right hippocampus has been associated with the use of
allocentric strategies (Burgess et al., 2002; Nedelska et al., 2012). The caudate nucleus and
parietal cortex are more so involved in egocentric strategies (Cook & Kesner, 1988; Iaria,
Petrides, Dagher, Pike, & Bohbot, 2003). Recent evidence further supported this concept, with
the caudate nucleus having greater involvement with motor abilities and the hippocampus being
12

involved with place memory in relation to spatial navigation performance (Daugherty & Raz,
2016).
Several analogs of spatial navigation tests utilized among animals, including the MWM,
Y-maze, and elevated plus maze, have been translated for human use (Harris, Wiener, &
Wolbers, 2012; Hort et al., 2007; Moffat & Resnick, 2002). There has been interest in studying
the impact of normal cognitive aging as well as cognitive impairment on spatial navigation
abilities. Particularly, if deficits related to these skills may reflect incipient cognitive decline
better than performance on traditional neuropsychological tests.
Spatial Navigation and Aging
Human analogs of the MWM have been helpful in examining spatial navigation
performance among older adults (Gazova et al., 2013; Moffat & Resnick, 2002). For example,
using a virtual version of the MWM young and old participants used distal visual cues to locate a
hidden platform. A probe trial and a cognitive mapping trial, where participants had to draw the
environment or the location of the hidden platform, were also given. Older and younger adults
completing these tasks had a different pattern of performance. When locating the hidden
platform, the distance traveled was greater for older adults than younger adults (Moffat &
Resnick, 2002). A similar relationship held true for the probe trials, where older adults spent less
time in the target quadrant than younger adults (Moffat & Resnick, 2002). Age effects were also
observed when considering the ability of participants to recreate a map of the testing arena,
particularly when identifying the location of the hidden platform. Taken together, these results
indicate that older adults may have more difficulty than younger adults with allocentric
navigation abilities, which require the use of distal visual cues. Evidence from another study of
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spatial navigation supports this claim, where allocentric navigation abilities were poorer for
those over age 70 as compared to their younger counterparts (Gazova et al., 2013).
When studying older adults and spatial navigation skills, it is important to consider how
volumetric measures of key brain structures as well as common neuropsychological tests
compare to virtual MWM performance (Moffat, Kennedy, Rodrigue, & Raz, 2007). Greater
distance to locate the hidden platform has been associated with smaller volume of the prefrontal
grey and white matter as well as the caudate nucleus (Moffat et al., 2007). Conversely, no
relationship was found between hippocampal volume and performance for older adults.
Performance on common neuropsychological tests have also been associated with virtual MWM
abilities. Better performance on neuropsychological tests of executive function, spatial memory,
and perceptual speed were associated with less distance to locate the hidden platform whereas
the opposite relationship was found between verbal abilities and the spatial navigation task
(Moffat et al., 2007).
While there has been substantial evidence indicating the use of the hippocampal regions
in spatial navigation performance among both animals (R. G. M. Morris, Garrud, Rawlins, &
O'Keefe, 1982) and humans (Nedelska et al., 2012), work presented by Moffat and colleagues
(2007) provided additional evidence for the use other brain regions during spatial navigation.
The lack of involvement of the hippocampus with navigation among older adults may indicate
the use of a different strategy or the recruitment of other brain regions as a compensatory
mechanism (Moffat et al., 2007). As the neuropsychological tests are not solely hippocampal
dependent measures, the association between these tests and MWM performance may further
indicate the importance of other brain regions in compensating for the age-related changes in
spatial navigation.
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While differences between younger and older adults in spatial navigation performance
have been evidenced, it is important to investigate the underlying mechanisms driving these
differences. One such reason for these differences may be due to search strategy. For instance,
when using a Y-maze paradigm, it was found that older adults were more likely to use an
egocentric strategy than an allocentric strategy as compared to younger adults (Rodgers,
Sindone, & Moffat, 2012). Older adults tended to select the goal arm based on start position
rather than the cues in their environment. This was also associated with performance on a virtual
version of the MWM task. Both younger and older adults that utilized the allocentric navigation
strategy had better performance on the MWM probe trial as measured by number of platform
crossings (Rodgers et al., 2012). Taken together, it appears that shifting to an egocentric
navigation strategy rather than using an allocentric strategy may lead to the changes observed in
spatial navigation performance with aging.
A virtual elevated plus maze to test navigation strategy also supports this claim (Harris et
al., 2012). Older adults had more difficulty in performance on an elevated plus maze task than
their younger counterparts. However, this relationship was driven by difficulty in changing
search strategy. Switching between egocentric and allocentric strategies to adequately perform
the task was more difficult for older adults than younger adults (Harris et al., 2012).
Results from the aforementioned studies have shown that older adults have deficits in
performance on human analogs of the MWM when compared to younger adults (Gazova et al.,
2013; Moffat & Resnick, 2002). These deficits may be related to age-related changes in brain
structures (Moffat et al., 2007). Older adults may also try to compensate for changes in spatial
navigation abilities by using different strategies. Using allocentric strategies may become more
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difficult and result in a shift to egocentric strategies instead (Harris et al., 2012; Rodgers et al.,
2012).
Spatial Navigation among Individuals with MCI and AD
Spatial navigation performance among those with MCI and AD has also been of interest.
Individuals with normal cognitive function, MCI, and mild AD have been tested on their route
learning abilities in a real-space environment (deIpolyi et al., 2007). Individuals with MCI and
mild AD had more difficultly in recreating a map of a newly learned route, locating the position
of a given landmark, and recognizing the order in which a specific landmark or location was
along the route as compared to the older adults with normal cognitive function (deIpolyi et al.,
2007). Therefore, tests of spatial navigation may prove to be a good tool for detecting cognitive
impairment.
Evidence from a human analog of the MWM has suggested that impairments are present
among those with MCI and AD as well (Hort et al., 2007). In a paradigm used by Hort and
colleagues (2007), participants were instructed to locate a hidden goal in a real space circular
arena using allocentric, egocentric or allocentric/egocentric navigation strategies over the course
of eight trials. An allocentric delayed test was also performed as well as computer versions of the
test. Across trials, greater difficulty in learning the task was observed for those with AD and
multiple domain (md) aMCI as compared to control participants (Hort et al., 2007). When testing
the average performance on each subtest (allocentric, egocentric, allocentric/egocentric,
allocentric delayed) individuals with AD and aMCImd had greater average distance error than
control participants. This was in contrast to those classified as aMCI single domain. These
individuals had greater average distance error on the allocentric and allocentric delayed tasks as
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compared to controls whereas similar performance was observed between those with subjective
memory complaints, naMCI, and control participants (Hort et al., 2007).
Among those with aMCI, additional research has found that spatial navigation
performance is related to hippocampal impairment subtype (Laczó et al., 2010). Differences
between participants classified as having hippocampal or nonhippocampal impairments were
observed for the hidden goal task. Participants with hippocampal impairment and aMCI did not
differ from those diagnosed with AD when considering allocentric, egocentric, or
allocentric/egocentric task performance (Laczó et al., 2010). Those classified as having
nonhippocampal impairment, however, had better performance on both the egocentric and
allocentric/egocentric subtests than their counterparts with hippocampal impairment (Laczó et
al., 2010). Thus, the hidden goal task appeared to be equally difficult for those categorized aMCI
with hippocampal impairment and participants with AD.
Hippocampal volume also impacts performance on the hidden goal task across cognitive
classifications (Nedelska et al., 2012). Among older adults classified as cognitively healthy,
MCI, or AD, right hippocampal volume, but not left hippocampal volume, was associated with
allocentric navigation abilities (Nedelska et al., 2012). Larger right hippocampal volume was
related to better performance on the human MWM for the allocentric trials, particularly among
individuals with MCI and AD.
In addition to the aforementioned MWM test described, other research teams have also
examined the influence of cognitive impairment and/or AD on spatial navigation performance
(Allison, Fagan, Morris, & Head, 2016; Benke, Karner, Petermichl, Prantner, & Kemmler,
2014). These studies are not a direct analogs of the MWM but instead focus upon the ability of
humans to learn new routes in a given environment. According to this work, greater difficulty in
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learning new routes and identifying landmarks have been observed among individuals with AD
and MCI as compared to cognitively healthy older adults (Benke et al., 2014).
Performance on an egocentric dependent task (route learning) and an allocentric
dependent task (wayfinding) has been explored among cognitively healthy individuals as
compared to those with preclinical or early-stage symptomatic AD (Allison et al., 2016).
Individuals classified as having preclinical AD had greater difficulty on the wayfinding task as
compared to the cognitively healthy individuals, however, this relationship did not hold true for
the route learning task (Allison et al., 2016). Further, the preclinical AD group had similar
performance to the early-stage symptomatic AD group for the wayfinding task, but not the route
learning task. Again, allocentric navigation tasks appear to be more difficult with cognitive
impairment.
Collectively, this body of research indicates that impairments in spatial navigation
abilities are apparent among those with MCI and AD (Allison et al., 2016; Hort et al., 2007;
Laczó et al., 2010). Deficits in both MWM performance for humans, rats, and mice have been
observed with aging and in disease states that are more common with aging in humans.
Therefore, the first study will examine the relationship between MWM performance among
humans and rats. Specifically, differences in performance will be examined in two ways: (1)
between age groups within species and (2) between species. The learning trials as well as the
probe trials will be compared and several hypotheses will be tested.
Hypothesis 1: It is predicted that older age will be associated with poorer performance
across learning trials for both rats and humans. When comparing young rats to old rats, old rats
will show poorer performance across trials than young rats. Similarly, among older adults,
greater age will be associated with poorer performance across trials. When the magnitude of
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differences observed among humans and rats are compared, it is predicted that age-related
differences will be more apparent among rats than humans. Further, the ability to translate from
rats to humans will be better aligned with the allocentric/egocentric and allocentric subtests due
to methodological similarities.
Hypothesis 2: It is predicted that older age will be associated with poorer performance for
probe or delayed trials for both rats and humans. When comparing young rats to old rats, old rats
will spend less time in the target quadrant than young rats. Similarly, among cognitively healthy
older adults, greater age will be associated with greater distance error in the allocentric delayed
trials. It is predicted that the magnitude of the differences between species (humans and rats) will
be similar.
Spatial Navigation and Biomarkers
There has also been interest in testing the relationship between biomarkers and cognitive
status. Regarding spatial navigation performance, several studies have examined the influence of
brain volume, particularly the hippocampus, on the ability to complete the given task (Moffat et
al., 2007; Nedelska et al., 2012). Genetic markers have been studied in relation to spatial
navigation abilities as well (Laczó et al., 2011; Laczó et al., 2015). Testing other blood based
biomarkers that may further impact the relationship between hippocampal volume and
navigation abilities could also be of benefit.
Apolipoprotein E (APOE) status may influence performance on a human analog of the
MWM (Laczó et al., 2011; Laczó et al., 2014). The APOE ɛ4 allele has been related to poorer
performance on tests of episodic memory, executive function, speed of processing, and global
cognition (Small, Rosnick, Fratiglioni, & Backman, 2004; Wisdom, Callahan, & Hawkins,
2011). Among individuals with aMCI, those carrying one or more ɛ4 allele had greater difficulty
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locating the hidden goal than their non-ɛ4 counterparts (Laczó et al., 2011). APOE ɛ4 carriers
had poorer performance on the allocentric, egocentric, and allocentric/egocentric tasks when
compared to non-ɛ4 carriers (Laczó et al., 2011). Interestingly, there were no differences in
performance on neuropsychological tests of verbal memory, executive function, working
memory, or attention by APOE status. Similar results were also observed when examining this
relationship on the virtual version of the task (Laczó et al., 2014). APOE ɛ4 homozygotes and
heterozygotes with aMCI had poorer performance on the allocentric, egocentric, and allocentric
delayed subtests than non-ɛ4 participants with aMCI (Laczó et al., 2014). Therefore, the hidden
goal task may be more sensitive in detecting subtle differences between ɛ4 and non-ɛ4 carriers
than traditional tests of cognitive status.
Proxy measures of iron deposition in the brain have been studied in relation to navigation
abilities among cognitively healthy adults (Daugherty & Raz, 2016). Deposition of iron in the
brain is believed to be the result of oxidative stress (Daugherty & Raz, 2015). When considering
search pattern length in a virtual MWM analog, the volume and level of iron deposition in the
caudate nucleus had a negative impact upon older adults. That is, smaller volume and greater
iron deposition was related to greater search pattern length at two-year follow-up (Daugherty &
Raz, 2016). Path complexity, on the other hand, was associated with hippocampal iron
deposition. Increasing levels of iron deposition in the hippocampus was associated with a more
complex route to locate the platform (Daugherty & Raz, 2016).
There has been interest in exploring biomarkers beyond volumetric measures (Korthauer
et al., 2016). Metabolites related to neuronal functioning, glial functioning, neurotransmission,
and inflammation including neuronal-axonal compound, glutamate and glutamine, choline, and
myo-inositol have been examined in relation to spatial navigation. The metabolites were not
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related to performance, however, there was a relationship between volumetric and white matter
integrity measures and spatial navigation (Korthauer et al., 2016).
Blood-based peripheral biomarkers have been related to spatial navigation performance
(Pařízková et al., 2017). Plasma homocysteine has been associated with spatial navigation
performance among older adults. Participants with higher levels of homocysteine had poorer
performance on a measure of allocentric-egocentric and egocentric navigation skills (Pařízková
et al., 2017). Further, this relationship only held true for individuals classified as having aMCI,
but not those with normal cognitive function or SCD. This provides support for underlying
biological mechanisms that have the potential to influence cognitive abilities.
Other Biomarkers of Interest
While the majority of the research on spatial navigation has focused upon identifying
brain regions associated with performance, it is also of benefit to examine the underlying
mechanisms driving this relationship. Biomarkers of interest to the study of aging include
anthropometric measures, balance and mobility, cardiovascular output, hormonal function,
metabolic function, and immune function (Lara et al., 2015). Of these biomarkers, blood glucose
levels may be of interest for further study. Among individuals with diabetes, deficits in cognitive
abilities and an increased risk for dementia have been reported (Arvanitakis, Wilson, Li,
Aggarwal, & Bennett, 2006; Mayeda et al., 2014; Xu et al., 2009). One of diagnostic feature of
diabetes is elevated glucose levels (American Diabetes Association, 2010).
High glucose levels have been related to risk for dementia even among those without
diabetes (Crane et al., 2013). With this in mind, several studies have aimed to examine the
relationship between glucose levels and cognitive functioning (Dahle et al., 2009; Seetharaman
et al., 2015). Among individuals with and without diabetes, higher fasting blood glucose has
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been associated with greater decline in processing speed and global cognitive abilities
(Seetharaman et al., 2015). A similar relationship has been observed among older adults without
diabetes, with higher HbA1c values associated with greater decline on a measure of global
cognitive functioning, the MMSE (Ravona-Springer et al., 2012). Other domains of cognitive
function have been shown to be influenced by glucose levels among those without diabetes,
including episodic and working memory performance (Dahle et al., 2009; Rolandsson,
Backestrom, Eriksson, Hallmans, & Nilsson, 2008).
Treatment with long-acting insulin, a glucose lowering hormone, among individuals
without diabetes has also been found to improve cognitive abilities (Claxton et al., 2015).
Participants with aMCI or early AD were found to have better performance on tests of
visuospatial skills and working memory following intranasal insulin dosing (Claxton et al.,
2015). Improvements in verbal memory performance were observed as well, but only among
those that were APOE ɛ4 carriers. With this considered, using glucose lowering medications
could have benefits to improving cognitive status. However, it is important to note that insulin
resistance also contributes to the relationship observed between cognition and glucose levels
(Willette et al., 2015; Willette et al., 2013).
There has also been research supporting a relationship between high glucose levels and
brain atrophy. For example, high normal levels of plasma glucose have been associated with
atrophy of the hippocampus (Cherbuin, Sachdev, & Anstey, 2012). Another study found that
hippocampal volume influences the relationship between HbA1c and verbal memory
performance; higher HbA1c levels were related to smaller hippocampal volume and worse verbal
memory performance (Kerti et al., 2013). If high glucose levels are damaging to hippocampal
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structures this could in turn influence navigation abilities, particularly with regard to allocentric
strategies.
As a growing body of evidence suggests a link between glucose levels and cognitive
status, further research testing this relationship in a spatial navigation test is important. As such,
several hypotheses will be tested.
Hypothesis 1: It is predicted that higher HbA1c levels will be related to poorer
performance on the hidden goal task. The magnitude of this effect may be larger among those
with MCI and AD as compared to healthy controls and individuals with subjective cognitive
decline.
Hypothesis 2: It is also of interest to examine the influence of HbA1c levels on hidden
goal task as compared to traditional neuropsychological tests. It is predicted that higher HbA1c
levels will not be related to poorer performance on neuropsychological tests. However,
differences in performance on these tests will be observed due to cognitive status.
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CHAPTER THREE:
STUDY 1 METHOD AND RESULTS

Method
Study 1 focused upon the ability to translate the MWM paradigm between rats and
humans. To do so, differences in performance within species and between species were
examined. Among rats, differences by age groups were compared for the ability to locate the
hidden platform. Among humans, differences by age groups were compared in the distance error
to locate a hidden goal. Following this evaluation within species, comparisons were be made
between species. This will provide greater insight for the ability to translate the MWM paradigm
from rats to humans.
Animals
Male Fisher 344 rats were selected from a prior study of nutrition, cognitive function, and
inflammation (Acosta et al., 2010). Aged (20 months) rats received either the nutritional
supplement NT-020 or the control treatment. Young (3 month) rats received the control
treatment. For the purposes of the current study, young (n=10) and aged rats (n=13) belonging to
the control group were analyzed. The previous study received approval from the Institutional
Animal Care and Use Committee.
Human Participants
Inclusion criteria for the current analyses were: complete hidden goal task data, complete
APOE genotype data, and geriatric depression scale (GDS) score less than 6. Participants
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classified as being cognitively healthy or having SCD were included in this study and have been
described elsewhere (Pařízková et al., 2017). Cognitively healthy participants had normal
neuropsychological test performance whereas participants in the SCD group had normal
neuropsychological test performance, reported issues with memory, had a Functional Activities
Questionnaire (FAQ) score ≤5, and had a Clinical Dementia Rating (CDR) global score ≤0.5.
Since these participants do not differ in neuropsychological test performance, data were
collapsed across diagnostic categories. Participants were further subdivided into two age groups:
young-old (age 53 to 70; n=30) and old-old (age 71 to 85; n=49).
Procedure
Rats. For the study of nutrition, cognitive function, and inflammation, administration of
the treatment occurred over a four week time frame. Behavioral testing using the MWM was
completed following the third week of treatment. Learning trials took place over the course of
five days, with a probe trial administered on the sixth day (Acosta et al., 2010).
Humans. Participants were recruited from the Motol University Hospital and 2nd Facility
of Medicine Memory Clinics in the Czech Republic. Individuals or informants reporting memory
complaints and referred by a physician, participants from the University of the Third Age, and
relatives of current patients and staff were recruited to the Czech Brain Aging Study (ChantiKetterl, Andel, Lerch, Laczó, & Hort, 2015; Pařízková et al., 2017). Participants had laboratory
data, neuropsychological, and hidden goal task data collected upon visits, which will be detailed
further. All participants had written and informed consent collected prior to the start of the study.
The institutional ethics committee of Motol University Hospital approved the study.
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Measures
Rats: Morris Water Maze. Rats were tested in the MWM as described by Acosta et al.
(2010). The testing apparatus consisted of a 1.5 meter in diameter pool filled with water. Below
the surface of the water and hidden from view of the rats was a 10 centimeter in diameter
platform. Rats were placed in the pool from one of four start locations (north, south, east, west)
across trials while the location of the hidden platform remained in a constant target quadrant for
each animal. Testing occurred over a period of five days, with four trials per day. Following the
fifth day of testing, two 30 second probe trials were given where the hidden platform was
removed and swim patterns were assessed.
The cumulative distance to reach the hidden platform was measured across learning trials
with the average performance for each day of testing calculated. Cumulative distance for each
trial was calculated as the time to reach the hidden platform by the distance traveled. The time
spent in the target quadrant was assessed for the two probe trials.
Human MWM analog: Hidden goal task. The hidden goal task (HGT) was completed
using a real space human analog of the Morris water maze and has been described elsewhere
(Hort et al., 2007; Kalová et al., 2005; Laczó et al., 2014). The testing apparatus is circular arena
2.9 meters in diameter enclosed by a dark blue curtain. Participants were first trained to locate a
hidden goal (red circle) based upon egocentric, allocentric, and allocentric/egocentric navigation
strategies on a computer version of the test. For the egocentric task, participants were required to
locate the hidden goal based upon their start position. For the allocentric task, participants were
required to locate the hidden goal based upon two distal visual cues. The allocentric/egocentric
task combined both these strategies, using the start position and distal visual cues to locate the
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hidden goal. Participants were also tested in an allocentric delayed task which was completed 30
minutes after the final allocentric trial.
After training on the computer version, these skills were transferred to the real space
version of the test. Trials of the real space version were conducted in the following order:
allocentric/egocentric, egocentric, and allocentric. Eight trials of the aforementioned tasks were
given; two trials of the allocentric-delayed task was given. The location of the hidden goal was
rotated clockwise across trials and the hidden goal was projected onto the floor prior to the task
and briefly following completion of each trial. Participants located the hidden goal by use of a
pointer stick. Distance error in locating the hidden circle was measured in centimeters.
For the current study, performance across eight trials were assessed for the
allocentric/egocentric, egocentric, and allocentric tasks as well as average performance for each
subtest. Distance error across trials was analyzed to test learning. The allocentric-delayed task
was used to test memory. Only the real space version of the test was used due to the cross species
comparisons with rats.
Covariates
There were not any covariates used for the rat portion of the study. Covariates for the
human portion of the learning trials included gender (male vs female), education (years), and
depressive symptoms (GDS score). APOE genotype (ɛ4 carriers vs non-ɛ4 carriers) was also
examined, as APOE ε4 status has been linked to spatial navigation performance (Laczó et al.,
2011; Laczó et al., 2014).
Analyses
Analyses were conducted for rats and human separately. T-tests were used to compare
differences between the two age groups (young and old) among rats for the average cumulative
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distance to the platform and average time spent in the target quadrant during the probe trial.
Similar comparisons were made for the human MWM analog, with average performance on the
real space egocentric, allocentric, and allocentric/egocentric trials compared between groups
(young-old and old-old). Average performance for the allocentric delay task was also compared
across groups. Recent evidence has suggested that reporting effect sizes and confidence intervals
may be more meaningful than null-hypothesis significance testing (Cumming, 2014). As such,
means and 95% confidence intervals were reported for the purposes of Study 1. Effect sizes were
also be calculated to compare the magnitude of differences between age and diagnostic group
within and across species.
In addition to examining the average performance, performance across trials was also
tested using a mixed-effect model (Singer & Willett, 2003). This model uses fixed and random
effects to provide an overall estimate for change while also taking into consideration that
individual trajectories of change may differ (Gueorguieva & Krystal, 2004). Mixed effect models
may be more advantageous for examining performance across trials than repeated measures
ANOVA due to variation in abilities to locate the platform or hidden goal between early and late
trials. When examining performance across trials for MWM data among rats and mice, the first
trials tend to be less correlated than later trials where animals have learned the task (Vorhees &
Williams, 2006; Young, Clark, Goffus, & Hoane, 2009). For the rat portion of the study, distance
to the platform was assessed for five blocks of learning trials whereas the eight trials for the
allocentric/egocentric, egocentric, and allocentric real-space HGT will be assessed among human
subjects. The effect of age group on MWM performance was examined for both rats and
humans. In addition, age was measured as a continuous variable and centered at age 70 for
human subjects.
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Results
Study 1 Age Comparisons: Rats
Mean Level Comparisons
Data from a total of 23 rats were used for the current analyses and were subdivided into
young (3 months; n=10) and old (20 months; n=13) age groups. Performance on MWM tasks
were evaluated with mean level and repeated measures comparisons. Results are further detailed
below. Independent samples t-tests were used to determine age differences in the total average
distance to locate the hidden platform and the average percent of time spent in the goal quadrant
for the probe trials. Results were significant for average cumulative distance, t(15.5)=4.26, p<.001,
d= 1.61, 95% CI [0.64, 2.55] with aged rats traveling a greater distance than their younger
counterparts. Results were also significant for average percent of time spent in the goal quadrant
t(11.5)=-3.67, p=.003, d=-1.70, 95% CI [-2.66, -0.72] with aged rats spending less time in the
target quadrant than young rats.
Data was also log transformed for analytical purposes. A similar pattern of results were
observed, with significant differences observed between age groups for average cumulative
distance to locate the hidden platform t(21)=4.05, p<.001, d=1.70, 95% CI [0.71, 2.65] and
average percent of time spent in the goal quadrant t(21)=-4.10, p<.001, d=-1.62, CI [-2.56, -0.65].
Aged animals had poorer performance than young animals for both tasks. MWM performance
for rats by age, including the mean, standard deviation, confidence intervals, and effect sizes are
reported in Table 1.
Across Trial Learning Comparisons
Mixed effects models were conducted to examine MWM performance over time. The
cumulative distance to locate the hidden platform (m) across five trials was assessed. The
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random effect of time was not used as inclusion of this parameter led to model convergence
problems. Additionally, linear, quadratic, and cubic effects of time (trials) were tested in the
unconditional growth model, with the quadratic function providing the best fit for the data as
indicated by the significant effect of time and model fit statistics (-2LL model fit of 1369.3 for
linear vs 1353.0 for quadratic vs 1352.8 for cubic effects of time). The change in model fit was
significant between the linear and quadratic effects of time, χ2=16.3, p<.01. The unstructured
covariance pattern was used for all models.
Results including fixed effects, random effects, and model fit are reported in Table 2 for
the no growth, unconditional growth, and conditional growth models. For the conditional growth
model, there was a significant linear effect of time (trials; Est=-85.56, SE=31.96, p=.001) and
age group (Est=125.91, SE=34.64, p<.001), but the linear and quadratic time by age group
interactions were all non-significant (p>.05). The results indicated that both young and old rats
were able to learn the location of the platform across trials as evidenced by the negative effect of
time. However, the significant effect of age showed that older rats had greater cumulative
distance to locate the platform than younger rats on the first trial. Spaghetti plots for the young
and aged animals are displayed in Figures 1 and 2. Average performance across trials by age
group are presented in Figure 3. Results for the log transformed data are reported in Table 3.
Study 1 Age Comparison: Humans
A total of 79 participants classified as being cognitively healthy or having subjective
cognitive decline were eligible for inclusion the human subject analyses. Participants were
subdivided into two groups: young-old (ages 53 to 70) and old-old (ages 71 to 85). Two
participants had average performance greater than 3.29 SD from the mean and were excluded
from the analyses. Seventy-seven participants were included in the subsequent analyses, with 47
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in the young-old group and 30 in the old-old group. Basic demographic characteristics are
included in Table 4. For the repeated-measures analyses, scores were replaced as missing if
greater than 3.29 SD from the mean in the remaining 77 participants. This resulted in missing
data for 1.95% of the allocentric, 2.11% of the egocentric, and 0.81% of the
allocentric/egocentric subtest samples.
T-tests and chi-squares were conducted to determine any differences between age groups
in years of education, gender, MMSE scores, GDS scores, and APOE genotype. There were no
differences in education, MMSE scores, and GDS scores between the young-old and old-old age
groups (ps>.05). The distribution of APOE e4 (non-e4 carriers vs e4 carriers) and gender was not
different between the two age groups (ps>.05).
Mean Level Comparisons
Independent samples t-tests were used to determine differences between age groups for
average distance error on the allocentric, egocentric, allocentric-egocentric, and allocentric
delayed subtests. Average performance was analyzed with complete data and outlier replaced
data (values >3.29 SD from the mean the repeated measures trials). HGT performance by age,
including the mean, standard deviation, confidence intervals, and effect sizes are reported in
Table 5.
For the complete data, there was not a significant difference between the young-old and
old-old age groups on the allocentric subtest, t(47.5)=1.49, p=.143, d=0.38, 95% CI [-.08, 0.84].
Non-significant results were also observed for the allocentric-egocentric subtest, t(75)=0.51,
p=.611, d=0.12, 95% CI [-0.34, 0.58] and the allocentric delayed subtest, t(75)=1.21, p=.231,
d=0.28, 95% CI [-0.18, 0.74]. There was, however, a significant difference between the youngold and old-old age groups on the egocentric subtest, t(75)=2.29, p=.025, d=0.54, 95% CI [0.07,
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1.00]. Participants in the old-old age group had poorer performance than the young-old age
group on the egocentric task.
A similar pattern of results were observed for the outlier replaced data across the
allocentric, allocentric-egocentric, and allocentric delayed subtests. There was not a significant
difference between the young-old and old-old age groups on the allocentric subtest, t(47)=1.42,
p=.161, d=0.36, 95% CI [-0.10, 0.82] or the allocentric-egocentric subtest, t(75)=1.36, p=.180,
d=0.32, 95% CI [-0.14, 0.78]. There also was not a significant difference between the young-old
and old-old age groups on the allocentric delayed subtest, t(39.3)=1.46, p=.154, d=0.39, 95% CI [0.07, 0.85]. In contrast to the complete data results, there was not a significant difference
between the young-old and old-old age groups on the egocentric subtest, t(75)=0.92, p=.363,
d=0.21, 95% CI [-0.25, 0.70].
Across Trial Learning Comparisons
Mixed effects models were conducted to examine HGT performance across trials. The
average distance error in locating the hidden goal across eight trials was assessed. The random
effect of time was not used as inclusion of this parameter led to model convergence problems.
Additionally, linear, quadratic, and cubic effects of time (trials) were tested in the unconditional
growth model. The linear function provided the best fit for the allocentric subtest data as
reflected by the significant effect of time and by model fit statistics (-2LL model fit of 5396.0 for
linear vs 5395.7 for quadratic vs 5392.7 for cubic effects of time). Model fit did not improve by
the addition of the quadratic effect, χ2=0.30, p>.05.The quadratic function provided the best fit
for the egocentric subtest data (-2LL model fit of 4824.8 for linear vs 4814.4 for quadratic vs
4812.5 for cubic effects of time) and allocentric/egocentric subtest data (-2LL model fit of
4888.0 for linear vs 4878.2 for quadratic vs 4878.0 for cubic effects of time). Change in model
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fit improved from the linear to quadratic effect of time for the egocentric subtest (χ2=10.4, p<.01
and the allocentric/egocentric subtest (χ2=9.8, p<.01). The unstructured covariance pattern was
used for all three subtests. Results for the continuous age variable are presented first, followed by
the categorical age groups.
Results including fixed effects, random effects, and model fit are reported in Tables 6, 7,
and 8 for the no growth, unconditional growth, and conditional growth models. A significant
effect of age (Est=0.82, SE=0.28, p=.003) was observed for the allocentric subtest. Older
individuals had greater distance error in locating the hidden goal than the younger individuals at
the first trial. There was also a significant trial x age interaction (Est=-0.11, SE=0.05, p=.039),
indicating that older participants were able to improve their performance on the allocentric task
more so than younger participants. A significant effect of both time (trial: Est=-3.67, SE=0.82,
p<.001; trial x trial: Est=0.37, SE=0.11, p<.001) and age (Est=0.53, SE=0.19, p=.006) were
observed for the egocentric subtest. While older participants had poorer performance on the first
trial, all participants were able to learn the task over time. A significant effect of time was
observed for the allocentric/egocentric subtest (trial: Est=-3.33, SE=0.80, p<.001; trial x trial:
Est=0.34, SE=0.11, p=.002). Performance improved across trials for the allocentric/egocentric
subtests irrespective of age.
In addition to testing the effect of age on a continuous scale for the HGT performance,
age group was also assessed using the cutoffs for the mean level comparisons (young-old vs oldold). Results are reported in Tables 9, 10, and 11. Results remained similar for the
allocentric/egocentric task. Differences between the two measures of age were present for the
allocentric and egocentric subtests. A non-significant trial x age interaction was observed (Est=1.63, SE=0.87, p=.061) for the allocentric task when assessing age as a categorical variable. For
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the egocentric task, there was not a significant age effect (Est=2.09, SE=2.69, p=.438) observed
for the categorical age measure whereas age modeled as a continuous variable was significant.
Learning across trials for each subtest are depicted in Figures 4, 5, and 6 using age as either a
continuous or categorical measure.
Cross Species Comparisons
Across species, age related differences were more apparent for rats than human subjects.
When considering the average cumulative distance to the platform (rats) versus the average
distance error (human subjects), a greater effect size was observed for the rats (d=1.61), 95% CI
[0.64, 2.55] than the human subjects for the allocentric/egocentric (d=0.32), 95% CI [-0.14,
0.78], allocentric (d=0.36), 95% CI [-0.10, 0.82], and egocentric (d=0.21), 95% CI [-0.25, 0.70]
HGTs. Similar results were observed for the probe trial among rats (d=-1.70), CI [-2.56, -0.65]
and allocentric delayed HGT (d=0.39), 95% CI [-0.07, 0.85] among human subjects. The
confidence intervals obtained for Cohen’s d further substantiate that age differences are more
apparent between young and aged rats than the human subject age groups.
For the repeated measures analyses, similar results were observed. Both young and aged
rats were able to locate the hidden platform over time. While rats from both age groups were able
to learn the task, old rats had greater cumulative distance for the first trial than their younger
counterparts. This is similar to the results observed among human subjects for the allocentric and
egocentric tasks with age as a continuous variable. However, this relationship was not observed
for the egocentric task when age was a classified as a categorical variable. While result of the
allocentric/egocentric subtest reflected learning over time, there was no effect of age as was
observed in the rat studies.
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CHAPTER FOUR:
STUDY 2 METHOD AND RESULTS

Method
Study 2 evaluated the relationship between spatial navigation abilities,
neuropsychological test performance, and a marker of glucoregulation among human subjects
classified as cognitively healthy, SCD, aMCI, and AD. This study will provide a greater
understanding for the relationship between blood glucose levels and neuropsychological test
performance as well as a real space and virtual analog of a human MWM paradigm.
Participants
To be included in the analyses, participants had to have neuropsychological and HGT
testing, HbA1c values, ≤ 60 days between laboratory, neuropsychological, or HGT data
collection, valid APOE genotype, and GDS scores below 6. Participants were classified into four
categories based upon cognitive status (cognitively healthy, SCD, aMCI, AD). Diagnostic groups
have been previously described (Kerbler et al., 2015; Laczó et al., 2011; Mokrisova et al., 2016;
Pařízková et al., 2017). Cognitively healthy participants were classified as such by normal
cognitive performance during neuropsychological testing. Those in the SCD group had normal
cognitive performance during neuropsychological testing, reported issues with memory, had a
Functional Activities Questionnaire (FAQ) score ≤5, and had a Clinical Dementia Rating (CDR)
global score ≤0.5. MCI of the amnestic subtype was examined in the current study; participants
classified as aMCI had memory impairments as reflected by neuropsychological test
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performance >1.5 SD below age and education matched means, FAQ score ≤5, and CDR global
score ≤0.5. Two classification guidelines were used to establish AD categorization: the
Diagnostic and Statistical Manual of Mental Disorders IV dementia diagnosis and National
Institute of Neurological and Communicative Disorders and Stroke and Alzheimer Disease
Related Disorders Association probable AD diagnosis. For analytic purposes, diagnostic groups
were combined in two ways. The first compared cognitively impaired (aMCI and AD) to nonimpaired (cognitively healthy and SCD). The second included combining participants classified
as cognitively healthy and SCD as compared to the aMCI and AD groups separately.
Of the 206 participants included in the cross sectional data, a total of 116 participants had
complete neuropsychological and HGT data and met other eligibility criteria. There were 23
participants with missing HbA1c values. Of those participants with HbA1c data, 21 individuals
had a time period >60 days between the laboratory measures, neuropsychological testing, or
HGT completion. Participants with a missing GDS score (n=10) or a score greater than six
(n=11) were also excluded. One participant was missing APOE genotype information. An
additional four individuals were classified as having naMCI and three individuals with uncertain
diagnostic status were not included in the sample.
Missing neuropsychological and HGT data were observed for 17 participants (n= 8 for
the AD group; n=9 for the aMCI group). The pattern of missing data was as follows: AVLT
trials 1-5 and AVLT 30 minute delay (n = 10), AVLT 30 minute delay trial (n= 2), COWAT and
the ROCF copy and immediate recall (n = 1), real space and virtual allocentric and allocentric
delay hidden goal (n=1), real space allocentric/egocentric, allocentric, egocentric, and allocentric
delayed hidden goal (n=2), and real space allocentric, egocentric, and allocentric day hidden goal
and AVLT tests (n=1). To combat the missing neuropsychological data, analyses were conducted
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in two ways: (1) Using the analytic sample with complete neuropsychological data (n=116) and
(2) Using multiple imputation for those with missing neuropsychological or HGT data (n=133).
Multiple imputation provides an estimate for missing data that is more accurate than traditional
measures of imputation (e.g. mean imputation) and allows data from the full sample to be
analyzed (Graham, 2009; Sterne et al., 2009).
Procedure
Participants were recruited from the Motol University Hospital and 2nd Facility of
Medicine Memory Clinics in the Czech Republic. Individuals or informants reporting memory
complaints and referred by a physician, participants from the University of the Third Age, and
relatives of current patients and staff were recruited to the study (Chanti-Ketterl et al., 2015;
Pařízková et al., 2017). Participants had laboratory data, neuropsychological, and hidden goal
task data collected. Only those with laboratory, neuropsychological, and hidden goal task data
within 60 days of collection were included in the current analyses. All participants had written
and informed consent collected prior to the start of the study. The institutional ethics committee
of Motol University Hospital approved the study.
Measures
Hidden goal task. The hidden goal task (HGT) was completed as described in
Experiment 1. The average distance error for the allocentric/egocentric, egocentric, and
allocentric subtests were analyzed. The delayed allocentric task was used to test memory.
Performance on both the real space and computer based versions of the test were assessed as
results are correlated with one another (Laczó et al., 2012).
Neuropsychological testing. Neuropsychological testing examined five cognitive
domains including verbal memory, nonverbal memory, working memory, visuospatial skills, and
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executive function and has been described elsewhere (Pařízková et al., 2017; Vyhnalek et al.,
2014). In addition, the Mini-Mental State Exam (MMSE; Folstein, Folstein, & McHugh, 1975)
was administered to assess global cognitive functioning. Information regarding the
neuropsychological tests used in this study are detailed below and in Table 12.
Verbal memory was assessed using the Rey Auditory Verbal Learning Test (RAVLT;
Bezdicek et al., 2014; Rey, 1964). The total score for the RAVLT trials 1-5 and the 30 minute
delay task was used. Nonverbal memory was measured using the immediate recall subtest of the
Rey Osterrieth Complex Figure Test (ROCF; Meyers & Meyers, 1995; Osterrieth, 1944).
Working memory was assessed using three tests including the digit span forward and backward
(Wechsler, 1981) as well as the Trail Making Test A (Bezdicek et al., 2012; Reitan, 1958; Reitan
& Wolfson, 1985). Visuospatial skills were measured using the complex copy version of the
ROCF Test (Meyers & Meyers, 1995; Osterrieth, 1944). Executive function was assessed by two
tests including the Trail Making Test B (Bezdicek et al., 2012; Reitan, 1958; Reitan & Wolfson,
1985) and the controlled oral word association test (COWAT; Benton, 1969; Loonstra, Tarlow,
& Sellers, 2001). The Trail Making Test A and Trail Making Test B were reverse scored for
analytic purposes. The maximum time to complete the Trail Making Tests were adjusted to 180
seconds and 500 seconds for tests A and B, respectively.
Depression. Depression was measured via the geriatric depression scale (GDS;
Yesavage, 1988). The 15 item version was used in the current study. Participants scoring greater
than or equal to six on this test were not included in the current analyses.
Glycosylated hemoglobin. For a description of laboratory measures, see Parizkova et al.
(2017). Glycosylated hemoglobin (HbA1c) was taken from whole blood samples and was
measured using high performance liquid chromatography. Laboratory measures obtained within
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60 days of HGT completion and neuropsychological testing were used for Study 2. HbA1c is
believed to be a relatively stable measure of blood glucose control, reflecting glucoregulation
over a two to three month period. HbA1c levels were log transformed to reduce skewness for the
variable.
Covariates
Covariates for the second experiment included age (years), gender (male vs female),
education (years), depressive symptoms (GDS score), and cognitive status. Diabetes was also
used as a covariate in the study, as greater HbA1c is indicative of diabetes.
Analyses
Differences between diagnostic groups (cognitively healthy, SCD, aMCI, AD) in
demographic characteristics, depressive symptoms, and APOE status were compared. Analysis
of variance (ANOVA) were conducted to determine differences in age, education, and depressive
symptoms. Tukey-Kramer post-hoc tests were conducted following a significant result. Chisquare tests of independence were conducted to determine differences in gender, APOE
genotype, and diabetes status by diagnostic status. All dependent variables (i.e.
neuropsychological test performance and HGT performance) were converted to z-scores
(Mean=0, SD=1) to ease interpretation of results. Analyses were conducted using the sample
with multiple imputation (n=133) as well as the sample with complete cognitive
neuropsychological and HGT data (n=116).
Multiple linear regression was used to assess the relationship between HbA1c and
cognitive measures. Three models were tested. In the first model, age, gender, education,
depressive symptoms, and diabetes status was examined in relation to HGT performance and
neuropsychological test performance. The addition of cognitive status and HbA1c were
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evaluated in the second model. The third model tested the HbA1c x cognitive status interaction.
Follow-up analyses were conducted for significant interactions for the complete data sample
using Process (Hayes, 2013). Process cannot be used for multiple imputation data. For the larger
sample utilizing multiple imputation, all dichotomous variables were effect coded and
interactions were tested. For dependent variables that were non-normally distributed,
bootstrapping techniques were used for the complete data sample.
Multiple imputation was completed in SAS using PROC MI. A total of 20 imputations
were performed using an inclusive method. Auxiliary variables for the imputation included age,
gender, GDS score, APOE genotype, HbA1c levels, diabetes status, and diagnostic group.
Imputation was completed for each missing test score and then converted to z-scores.
Power analyses were calculated using G*Power to determine an adequate sample size.
With a power of .80 and a two-tailed alpha of 0.05, a sample size of 118 participants would be
needed. This would detect a moderate f2 effect size of 0.15. Analyses were completed using SAS
version 9.3 and alpha levels were set at 0.05.
Results
Participants
A total of 116 participants were included in the complete sample and 133 participants
were included in the multiple imputation sample. There were no significant differences between
the two samples regarding participant characteristics (ps>.05). Therefore, characteristics are
described for the multiple imputation sample in Table 13 by diagnostic category.
ANOVAs with Tukey-Kramer post-hoc tests were conducted to examine differences in
age, education, MMSE scores, GDS scores, and HbA1c levels. A significant difference was
observed for age, F(3, 129)=10.70, p<.001. Participants classified as aMCI were older than those
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classified as cognitively healthy or with SCD (ps<.05). Additionally, participants classified as
having AD were older than those with SCD. Differences in educational attainment were present
as well, F(3, 129)=3.99, p=.009 with participants in the aMCI and AD group having fewer years
of schooling than the cognitively healthy participants (p<.05). MMSE scores varied by
diagnostic category, F(3, 129)=86.43, p<.001. The aMCI group had lower MMSE scores than
both the cognitively healthy and SCD groups in addition to the AD group having lower scores
than all other diagnostic categories (ps<.001). Finally, a significant difference was observed for
GDS scores, F(3, 129)=7.65, p<.001. Cognitively healthy participants reported fewer depressive
symptoms than all other diagnostic category groups (ps<.05). There were no significant
differences in HbA1c levels.
Chi-square tests were conducted to determine differences in the distribution of gender,
APOE genotype, and diabetes status. There was not a significant difference in the distribution of
gender across diagnostic category (p>.05). There was a significant difference in the distribution
of APOE genotype across diagnostic category, with participants with aMCI and AD more likely
to be APOE e4 carriers, χ2 (3, N=133)=13.61, p=.004. The distribution of diabetes also differed
by diagnostic category, χ2 (3, N=133)=9.65, p=.022. There was a greater proportion of
individuals with diabetes in the AD group.
Multiple Regression
Multiple regression analyses were conducted to test the relationship between cognitive
performance and HbA1c levels. Analyses were conducted in two ways regarding cognitive
status: (1) using one variable coded as cognitively impaired vs non-impaired (2) using two
variables coded as aMCI vs the non-impaired and AD group and AD vs the non-impaired and
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aMCI groups. Results for the complete sample and the multiple imputation sample are described
below.
Correlations between the variables included in the regression analyses are reported in
Table 14 for the complete sample and Table 15 for the multiple imputation sample. In general,
poorer neuropsychological and HGT performance was associated with cognitive impairment,
greater age, fewer years of education, and greater number of depressive symptoms. Gender was
not significantly correlated with cognitive performance. HbA1c was only associated with
executive function. HbA1c was significantly correlated with diabetes, r(131)=.66, p<.0001 and
APOE e4 genotype was significantly correlated with classification of cognitive impairment,
r(131)=.32, p<.001.
Complete Sample Multiple Regression
Cognitive impairment classification. No significant relationships were observed
between HbA1c or HbA1c x cognitive impairment and the virtual and real space HGTs (ps>.05).
There were also not a significant relationship observed between HbA1c or HbA1c x cognitive
impairment and verbal memory, nonverbal memory, working memory, and visuospatial skills
(ps>.05).
A significant relationship was observed in the regression models for executive function
and HbA1c and is reported in Table 16. Age, education, and depressive symptoms were
significant predictors of executive function performance in Model 1. The addition of cognitive
impairment group and HbA1c in Model 2 were significant predictors of executive function as
well. Model 2 accounted for an additional 14% of the variance as compared to Model 1. A
significant relationship was observed for HbA1c and executive function in Model 2 (beta=-2.48,
SE=0.92, β=-0.28, p=.008). The Model 3 interaction term (HbA1c x cognitive impairment) was
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also a significant predictor of executive function. There was a 2% change in variance from
Model 2 to Model 3, with the variables included in Model 3 accounting for 40% of the total
variance. The interaction between HbA1c and cognitive impairment was significant, (beta=-2.97,
SE=1.44, β=-0.14 p=.041).
Follow-up analyses using the pick-a-point approach were conducted to evaluate the
relationship between cognitive impairment, HbA1c levels, and executive function. There was no
significant relationship between HbA1c and executive function for participants in the nonimpaired group (beta=-1.39, SE=1.05, β=-0.13, p=.188, 95% CI [-3.46 to 0.69]). There was a
significant relationship observed between HbA1c and executive function for those classified as
cognitively impaired (beta=-4.35, SE=1.28, β=-0.40, p=.001, 95% CI [-6.90, -1.81]). For
participants that were classified as aMCI or AD, higher HbA1c levels were associated with
poorer performance on measures of executive function.
Cognitive group classification. No significant relationships were observed between
HbA1c or HbA1c x cognitive group and the virtual and real space HGTs (ps>.05). There were
also no significant relationships observed between HbA1c or HbA1c x cognitive impairment and
verbal memory, nonverbal memory, and working memory, and visuospatial skills (ps>.05).
Similar to the results with cognitive impairment status, a significant relationship between
HbA1c and executive function was observed and is reported in Table 17. Age, education, and
depressive symptoms were significant predictors of executive function performance in Model 1.
The addition of cognitive group and HbA1c in Model 2 was also significant. Model 2 accounted
for an additional 17% of the variance as compared to Model 1. A significant relationship was
observed for HbA1c and executive function in Model 2 (beta=-2.30, SE=0.90, β=-0.26, p=.012).
The addition of the interaction term in Model 3 was significant as well. However, the interaction
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terms did not improve the fit of the regression (p=.160) and the interaction between HbA1c and
cognitive group was not significant for the aMCI comparison group (beta=-2.69, SE=1.43, β=0.25, p=.063) or AD comparison group (beta=-3.54, SE=5.55, β=-0.33, p=.525). HbA1c did not
influence executive function performance for the cognitively normal or SCD group (beta=-1.32,
SE=1.03, β=-0.12, p=.204) and the AD group (beta=-4.86, SE=5.55, β=-0.45, p=.384). A
significant relationship between HbA1c and executive function was observed for the aMCI group
(beta=-4.01, SE=1.28, β=-0.37, p=.002).
Multiple Imputation Sample Multiple Regression
Cognitive impairment classification. No significant relationships were observed
between HbA1c or HbA1c x cognitive impairment and the virtual and real space HGTs (ps>.05).
There were also no significant relationships observed between HbA1c or HbA1c x cognitive
impairment and verbal memory, nonverbal memory, and working memory (ps>.05).
There was a significant relationship observed between HbA1c and executive function
(beta=-1.83, SE=0.85, β=-0.17, p=.029) in Model 2. The executive function HbA1c relationship
(beta=-2.13, SE=0.85, β=-0.19, p=.012) and the interaction between HbA1c and cognitive
impairment (beta=-2.81, SE=2.97, β=-0.13 p=.029) were also significant as measured in Model
3. Estimates are reported in Table 18. Further examination of the relationship between HbA1c
and executive function by cognitive impairment classification was conducted. There was not a
significant effect of HbA1c on executive function performance for the non-impaired group
(beta=-0.42, SE=0.81, 95% CI [-2.01, 1.16], β=-0.04, 95% CI [-0.18, 0.11] p=.600). Results for
the participants classified as cognitively impaired were also non-significant but exhibited a trend
for higher levels being associated with poorer performance (beta=-3.14, SE=1.63, 95% CI [-6.33,
0.05], β=-0.29, 95% CI [-0.58, 0.00] p=.053).
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In addition to executive function, there was a significant relationship between HbA1c and
visuospatial skills (beta=2.26, SE=1.12, β=0.21 p=.044). The interaction was not significant
(p=.877). Higher HbA1c levels were associated with better visuospatial performance. It is
important to note, however, that this may be the result of non-normally distributed data. When
using bootstrapping techniques in the complete data sample, results were not significant for the
relationship between HbA1c and visuospatial skills.
Cognitive group classification. No significant relationships were observed between
HbA1c or the HbA1c x cognitive group interaction and the real space and the allocentric,
allocentric/egocentric, and allocentric delayed virtual HGTs (ps>.05). There were also no
significant relationships observed between HbA1c or HbA1c x cognitive impairment and verbal
memory, nonverbal memory, and working memory (ps>.05).
There was a significant relationship between HbA1c and visuospatial skills (beta=2.19,
SE=1.04, β=0.20, p=.034). The interaction was not significant (p=.729 and .494 for the aMCI
and AD comparison groups, respectively). Again, it is important to note that the relationship was
not significant when using bootstrapping techniques with the complete sample data.
A significant relationship was observed between HbA1c and executive function (beta=1.90, SE=0.81, β=-0.17, p=.018) as assessed in Model 2. There was not a significant interaction
between HbA1c and the aMCI comparison group (beta=-2.17, SE=1.32, β=-0.09, p=.102) or AD
comparison group (beta=-1.91, SE=2.33, β=-0.06, p=.414) in Model 3. Estimates are reported in
Table 19.
Finally, the interaction between HbA1c and cognitive group was nearly significant for
virtual egocentric navigation performance for the AD comparison group (beta=-5.07, SE=2.69,
β=-0.46, p=.062). Although not significant, HbA1c had greater influence on those in the AD
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(beta=-4.86, SE=2.71, β=-0.44, p=.076) group as compared to individuals classified as aMCI
(beta=-0.57, SE=1.32, β=-0.05, p=.667) or cognitively healthy and SCD (beta=0.22, SE=1.10,
β=0.02, p=.845).
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CHAPTER FIVE:
DISCUSSION

The aims of the current dissertation were twofold. One goal was to determine the
translational ability of the MWM between species, which has been examined in Study 1. The
second goal of the disseration was to evaluate the effect of a biomarker of glucose control on
cognitive status as measured in Study 2. With the goals of the dissertation considered, the
discussion will examine results of both Study 1 and Study 2. The results of each study will be
evaluated by the respective research hypotheses and are further detailed below. Strengths,
limitations, and suggestions for future research will also be provided.
Study 1
Study 1 examined the effects of age on MWM performance among both rats and human
subjects. It has been well established that spatial navigation performance is poorer with older age
(Gazova et al., 2013; Guidi et al., 2014; Moffat & Resnick, 2002; Shukitt-Hale et al., 1998).
However, few cross species studies exist directly examining this relationship. As such, the goal
of Study 1 was to evaluate and compare age-related deficits in spatial navigation for rats and
human subjects. The cross-species comparisons are useful for evaluating the translatability of
MWM data. Understanding between species similarities in performance will be helpful for
establishing interventions to improve cognitive function.
A further discussion of the results by each research question will follow. The first
research hypothesis postulated that age differences in MWM performance will be present, but the
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deficits will be more pronounced among the rats than the human subjects. To address the first
research hypothesis, mean level and across learning trial comparisons for the MWM were
evaluated. The relationship between age and MWM performance will be discussed for within
and between species differences. The second research hypothesis predicted that age-related
deficits in probe and allocentric-delayed trials would be observed, with rats and human subjects
showing a similar level of impairment. To address the second research hypothesis, mean level
comparisons were examined for the probe (rats) and allocentric delayed (humans) trials. Again,
differences in peformance within and between species will be further evaluated. Finally, the
strengths and limitations of Study 1 along with furture directions for research will be provided.
Mean Level and Across Learning Trial Comparisons
Rats. For the rats, mean level comparisons suggested that aged animals had poorer
performance than young rats for the average cumulative distance to locate the platform. The
difference between the young (3 month) and aged (20 month) animals were found to be large,
with an estimated Cohen’s d of 1.61. Calculating the 95% confidence intervals for Cohen’s d
further validated this point, with the estimated effect size falling between 0.64 and 2.55. Results
were similar when the data was log transformed to deal with non-normality of the distribution,
d=1.70, 95% CI [0.71, 2.65].
Across trial learning analyses revealed age differences in performance on the first day of
training, but not across trials. Both young and aged rats were able to learn the location of the
hidden platform at a similar rate as indicated by the absence of a trial by age interaction. Both the
mean level comparisons and the across learning trial comparisons are in concordance with
previous research (Lindner, 1997; Shukitt-Hale et al., 1998). Aged rats typically have poorer
MWM performance than their younger counterparts, with differences emerging by at least 18
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months of age (Shukitt-Hale et al., 1998). Although variability in MWM performance has been
noted between aged rats (Lindner, 1997), the random effect of time could not be estimated across
trials in the current study. However, the random effect of the intercept did indicate variability
between rats for the first trial day.
Humans. Results from the human subjects by age group did not differ when considering
mean level performance for the allocentric, egocentric, or allocentric/egocentric subtests. When
calculating an effect size, a small to medium difference was observed for each subtest (d=0.36
for allocentric, d=0.21 for egocentric, and d=0.32 for allocentric/egocentric). The confidence
intervals for estimated effects sizes, however, further suggest that there are not differences
present between the age groups when assessing mean level comparisons. Therefore, examining
mean-level performance may not be the best way to examine age differences in human subjects.
Age-related differences in the HGT for the allocentric and egocentric subtests were
observed for human subjects, with older age related to greater distance error for the across
learning trials. Participants, however, were able to learn the task over time for both the
allocentric and egocentric trials. Older participants even had a greater rate of learning than
younger participants for the allocentric trial. No age differences were observed for the
allocentric/egocentric subtest, perhaps due to the lack of difficulty with the task.
Differences observed for age when measured as a continuous variable versus a
categorical variable should also be discussed. While an effect of age was clearly observed for
both allocentric and egocentric tasks using the age-centered measure, these results did not hold
true for the categorical age group analyses. For instance, there was not an effect of age on
egocentric task performance. There was also not a significant age by time interaction for the
allocentric task. These differences could be due in part to strategy preference. Prior research has
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found that when allocentric navigation skills become difficult with age, older adults tend to
switch to egocentric strategies (Harris et al., 2012; Rodgers et al., 2012). Using age as a
continuous measure may better take into account the shift in navigation strategy with age.
Further, the lack of findings with mean level comparisons suggests that the age group cutoffs
may not be precisely capturing differences in HGT performance.
Learning Trials: How do Species Compare?
When considering average performance, differences were apparent only for the rats.
Therefore, average performance may not be a sensitive enough metric to detect age- related
differences. Data from the learning trials gives a more precise estimate of the age-associated
changes observed with spatial navigation. For the HGT among humans, age differences were
only present when examining allocentric and egocentric subtests, but not the
allocentric/egocentric task when using age as a continuous variable. Results were not significant
for the egocentric subtests when age was a categorical variable. Taken together, these results
further validate the use of the allocentric subtest for comparison with animal models.
There are several factors that may contribute to the differences observed in MWM
abilities between rats and humans. One of which is methodological issues. The rat and human
version of the MWM follows a slightly different protocol. A recent publication by Laczó,
Markova, et al. (2017) tested a completely analogous protocol for cognitively healthy young rats
and humans using medications known to hinder (scopolamine) or potentially improve
(donepezil) spatial navigation performance. Results of the study provided evidence for the
translational efficacy of the HGT among human subjects. Administration of scopolamine had a
similar effect for young rats and humans with greater difficulty in locating the hidden platform
observed. Administering donepezil did not alleviate the deficits observed from scopolamine
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among humans whereas a significant rescue effect was observed in rats for the learning trials
only (Laczó, Markova, et al., 2017). The results are similar to those observed in the current
study, with the within group differences being greater among rats than humans.
It is also important to note that sex differences may play a role in the between species
discrepancies. Only males were used in the rat analyses. This is in contrast to the human results
where more than half of the sample was female (62.3%). Sex differences in spatial navigation
abilities have been evidenced in both rats (Rodriguez, Torres, Mackintosh, & Chamizo, 2010)
and human subjects (Korthauer, Nowak, Frahmand, & Driscoll, 2017) with males having better
performance than females. However, sex differences were not observed in a previous study
utilizing this data (Gazova et al., 2013). Further, there was no young age group for comparisons
among human subjects. The lack of findings for the mean-level comparisons could be explained
by the lack of variation in age groups.
Memory Trials
Rats. Performance on the probe trials indicated significant differences between the age
groups. The young rats spent significantly more time in the target quadrant than their older
counterparts. However, it is important to note that the aged animals did not perform above
chance (>25%) for the probe trials. The average time spent in the target quadrant for aged rats
was 24.41% versus 39.99% for the young rats, with a large effect size reported (d=-1.61).
Although both the young and aged rats are able to learn the location of the platform, only the
young rats indicated the ability to recall the location following training.
Humans. No age-related differences were observed between the young-old and old-old
participants for the allocentric delayed trials. A medium effect size was calculated for the
difference in performance between young-old and old-old participants. However, the 95%
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confidence interval [-0.07, 0.85] for the effect size further provided evidence for the nonsignificant relationship. There were only subtle differences between the age groups analyzed for
the memory measure.
Memory Trials: How do Species Compare?
Between species differences were observed for the probe and allocentric delayed trials.
For the probe trials, aged rats spent less time in the target quadrant than their younger
counterparts. While a significant difference was observed, it is unlikely that the aged rats were
able to recall the former location of the hidden platform. No differences were present between
the young-old and old-old human subjects for the allocentric-delayed trials. The difficulty of the
probe and allocentric-delayed may explain these results. The probe test and the allocentricdelayed trial may not be the best metric when testing across species comparisons.
Strengths
The cross species comparisons were a major strength of Study 1. By comparing
performance between rats and humans greater insight into accurate translation can be
determined. Additionally, multiple measures of performance were analyzed. Results indicated
that assessing the learning trials rather than mean level performance is more advantageous when
determine age-related changes. The results also reflected the limited utility of the probe trials and
allocentric delayed trials in translation. It appears that this task may be too difficult for aged
subjects, particularly among the rats.
Limitations
There are several limitations regarding this study. For instance, the methodology is not
precisely the same between the rats and human subjects. Differences in methodology between
species may account for some of the discrepancies in observed outcomes. However, it may show
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that MWM methodology does not need to be an exact replicate between species to test the effect
of age on performance. Another limitation is the age of the rats versus the human subjects. The
animals used in the current analyses were younger than the human subjects analyzed. While ages
were not directly equivalent, results still provide insight about age-related changes in spatial
navigation abilities.
Implications for Future Research
The collective results of Study 1 provides further evidence that age-related changes in
spatial navigation performance can be translated between species. Future research could compare
search strategies, something that was not done in the current study. Search strategies by age
could be compared between species or used as a control variable. It may also be interesting to
test latency measures for mouse or rat models to see how this metric compares to distance error
in human subjects.
In addition to the testing the aforementioned measures of MWM performance, the ability
to translate between mice, rats, and human regarding age-related deficits in performance should
be more extensively examined as well as in various models of disease. Impairment among aged
animals has been measured in several different ways across studies. For instance, rats performing
in the lower 30% of the sample have been classified as being cognitively impaired (Drapeau et
al., 2003) while other studies have created a discrimination index based upon probe trial
performance (Guidi et al., 2014). Therefore, it would be of interest to test different metrics of
classifying cognitive impairment among rats and mice as compared to human subjects. For
instance, rats performing 1.5 SD below the mean of their age-matched counterparts on MWM
performance could be classified as having MCI. The MCI classification could then be compared
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between species. However, selecting similar methods may not accurately capture the cognitive
profile observed in each species with impairment.
When considering models of disease states, animal models of AD could be compared to
human subjects with AD regarding MWM performance. This could be completed across the
several mouse models of AD currently utilized in research (e. g. 3xTg, 5xFAD, PS19Tg) to see
which one best translates to the behavioral challenges exhibited by those with AD. A recent
study by Possin and colleagues (2016) has utilized cross-species methodology, comparing
between early-stage AD mice and human subjects with cognitive impairment. Overall,
similarities were observed between the cognitively impaired mice and humans, whereby
performance across MWM testing was poorer than their cognitively healthy counterparts (Possin
et al., 2016). However, early learning trials found that the magnitude of differences between
mice was greater than that between humans, which was similar to the results of the current study.
While the MWM provides an excellent tool for testing translation between species, other
behavioral tests should be examined as well. Other maze-type tests, including the T-maze, Ymaze, or radial arm maze would be excellent candidates for testing the efficacy of translation.
Evaluating more complex measures of spatial navigation, such as the ability to recreate mental
maps among humans, would also be interesting to compare to simple metrics of the MWM
among rats and mice. Testing domains other than spatial navigation are of utmost importance as
well. For instance, tests of social recognition could be a potential target for translation as it
would be somewhat easy to study between species. Once greater accuracy in translating
behavioral paradigms between species is established, adding in biomarkers related to cognitive
function to explain underlying mechanisms of action would be of interest.
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Age-related changes in cognition have been and continue to be thoroughly investigated in
research. The results of Study 1 add to this research by examining the performance of both rats
and human subjects on a MWM task. With greater knowledge of age-related cognitive changes
has come greater study of interventions to delay cognitive decline. Almost always, interventions
are tested in animal models before being applied to human subjects. We therefore must ensure
that translation between species is accurate in order for treatments to properly work. Precise
translation will lead to more targeted interventions to improve cognitive decline.
Study 2
The second study tested the relationship between HbA1c levels, spatial navigation
performance, and neurocognitive performance among human subjects. There has been extensive
research examining the negative effects of elevated blood glucose levels on cognitive abilities
(Dahle et al., 2009; Kerti et al., 2013; Ravona-Springer et al., 2012; Yaffe et al., 2012). There has
also been evidence of poorer spatial navigation abilities being indicative of incipient cognitive
decline (deIpolyi et al., 2007; Hort et al., 2007; Verghese, Lipton, & Ayers, 2017). Taken
together, it is of interest to examine the impact of blood glucose levels on tests which are more
sensitive to subtle cognitive changes. The first research hypothesis of Study 2 suggested that
higher HbA1c levels would be associated with poorer spatial navigation abilities. The second
research hypothesis postulated that HbA1c levels would have little impact on common tests of
neuropsychological functioning.
The results of Study 2 will be discussed by each of the aforementioned hypotheses. The
first portion will examine the results of the HbA1c and spatial navigation relationship as
measured by multiple regression. The second portion will discuss the influence of HbA1c on
commonly used tests of neuropsychological function. Comparisons between the results of the
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HGT, a human MWM analog, and the neuropsychological evaluations will also be made.
Finally, limitations, strengths, and future directions for research will be evaluated.
HbA1c and Spatial Navigation Performance
The association between HbA1c and spatial navigation performance was tested across
four subtests of the HGT in both the virtual and real space environment. Results suggested that
HbA1c had little impact on spatial navigation performance. No significant relationships were
observed between HbA1c and performance on the allocentric/egocentric, allocentric, egocentric,
or allocentric-delayed hidden goal subtests.
Tests of spatial navigation are believed to be more sensitive to detecting early changes in
cognitive function (deIpolyi et al., 2007; Hort et al., 2007). Therefore, one would anticipate
biomarkers related to cognitive impairment to have a greater impact on spatial navigation skills
than traditional neuropsychological test measures. Further, there has been research suggesting
high normal glucose levels are associated with atrophy of the hippocampus (Cherbuin et al.,
2012; Kerti et al., 2013) and that larger right hippocampal volume leads to better spatial
navigation performance (Nedelska et al., 2012). While the results did not support this hypothesis,
there may be several reasons for the null findings.
One such reason may be due to the lack of variability in HbA1c levels. The average
HbA1c level for the overall sample was 5.96%, with a minimum HbA1c value of 4.99% and a
maximum HbA1c value of 8.56%. It may also be of interest to study performance across the
learning trials for the HGT subtests. As indicated by Study 1, learning across trials may be more
sensitive to subtle nuances of spatial navigation performance. Determining the relationship
between HbA1c levels and learning curves for HGT performance may reveal deficits not present

56

at the aggregate level. However, regression models utilizing average performance provided the
best metric to compare between the HGT and common neuropsychological tests.
HbA1c and Neuropsychological Testing
There was not a significant association between HbA1c levels and verbal memory,
nonverbal memory, or working memory. A significant relationship was observed between
visuospatial skills and HbA1c levels. However, this was only observed in the multiple
imputation sample and may be a result of non-normally distributed data. The lack of findings for
both verbal and working memory are somewhat surprising considering higher fasting blood
glucose and HbA1c levels have been associated deficits in memory (Dahle et al., 2009; Kerti et
al., 2013). This discrepancy may be explained by differences between samples in the health of
participants. In the aforementioned studies, participants were cognitively healthy and did not
have diabetes whereas this was not exclusion criteria for the current study.
While there was no association between memory and glucose levels, a significant
relationship was observed between HbA1c and executive function. Higher HbA1c levels were
associated with poorer executive function performance. Subsequent moderation analyses found
that HbA1c levels had greater impact on executive function for those classified as being
cognitively impaired. HbA1c levels were not a significant predictor of executive function among
those without cognitive impairment. A marginally significant relationship between HbA1c and
executive function was also observed for the cognitively impaired group using the multiple
imputation sample. When examining the relationship between HbA1c and cognitive group, it
was found that only those classified as having aMCI had poorer executive function performance
with higher glucose levels. Deficits in executive function and memory are believed to be the
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first signs of cognitive decline (Albert et al., 2007). The results of the current study suggest that
HbA1c further exacerbates the cognitive deficits observed among those with aMCI.
The impact of diabetes upon executive function has been well documented, with higher
glucose levels in the presence of this condition associated with poorer executive function (Yaffe
et al., 2012; Zhao et al., 2015). The relationship between diabetes, glucoregulation, and executive
function could not directly be tested in the current study, as only 15% of the participants had
diabetes. However, the results of this study add to prior research suggesting a link between
elevated glucose levels and executive function. Exposure to higher faster plasma glucose levels
throughout midlife have been associated with poorer performance in this cognitive domain
(Yaffe et al., 2014).
It may also be that insulin resistance, rather than elevated glucose levels alone, are
detrimental to cognitive health. There appears to be a relationship between insulin resistance and
cognition, which includes executive function. For instance, insulin resistance has been associated
with greater difficulty in completing the Trail Making Time B test (Abbatecola et al., 2004) and
greater decline in verbal fluency abilities (Ekblad et al., 2017). Further, a link between a gene for
glucose regulation, insulin degrading enzyme (IDE), and executive function has been evidenced
(McFall et al., 2014). Participants with the high risk allele had poorer performance than their
counterparts with the protective allele (McFall et al., 2014). Taken together, this research
suggests that factors contributing to glucose regulation can impact cognitive status.
Differences Observed in Executive Function and Spatial Navigation
While there was a significant finding for the executive function measure, HbA1c had no
impact on spatial navigation performance. It is important to note a recent study which found that
spatial navigation is a unique cognitive construct (Laczó, Andel, et al., 2017). Through principal
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components analyses, spatial navigation was identified as measuring a different domain than
executive function, working memory, verbal memory, nonverbal memory, language, or
visuospatial skills in a sample of participants with normal cognitive functioning and aMCI. This
study also demonstrated that executive function was a significant predictor of allocentric
navigation skills, but only among those with aMCI and not normal cognitive functioning (Laczó,
Andel, et al., 2017).
Although results did not show a direct link between spatial navigation and HbA1c, the
association observed with executive function may provide some additional insight. Skills such as
planning a route require executive function abilities in order to be successfully completed.
Perhaps a different task of spatial navigation, such as route learning, would better detect the
impact of HbA1c on spatial navigation performance. Further, better performance on measures of
executive function including category fluency and a color-word association test have been
associated with better spatial navigation skills among younger adults (Korthauer et al., 2017).
With this considered, it would be interesting to examine the relationship between spatial
navigation abilities and HbA1c levels when controlling for executive function performance in the
Study 2 sample.
Strengths
There are several strengths of Study 2 that should be noted. First, there were a variety of
cognitive tests examined. The study included tests of spatial navigation, as well as
neuropsychological tests measuring verbal memory, nonverbal memory, working memory,
visuospatial skills, and executive function. Having a breadth of assessments allowed for
comparison between commonly used neuropsychological tests (e.g. Trail Making Tests,
RAVLT) and tests believed to be more sensitive to cognitive impairment (hidden goal task).
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Another strength of the study was the different cognitive groups examined, which included
participants that were classified as cognitively healthy, SCD, aMCI, and AD. By including
participants across a spectrum of cognitive functioning, we were able to see if cognitive
performance was differentially effected by glucose levels. Finally, glucose regulation was
measured by HbA1c, which provides a two to three month estimate of relative glucose levels.
Using HbA1c may be more advantageous than measures such as fasting blood glucose.
Limitations
While there are strengths of the study, there are also limitations. One such limitation may
be with the imputation sample. While only a small portion of the sample required imputation
(12.8% total), it was only for those classified as aMCI or AD. Therefore, data was not missing
completely at random. The study is also cross-sectional, which does not allow for causality to be
determined. One measure of blood glucose was examined which may not capture fluctuations in
glucoregulatory abilities and medication usage among diabetic participants were not taken into
account. It would be useful to study the relationship between the duration of blood glucose
dysregulation and cognition status. This may involve studying glucose levels in mid-life as
compared to older age, which was not able to be tested in the current study.
Finally, the sample lacked racial diversity. It would be hard to generalize the results to
the population of the United States. This is particularly important as rates of diabetes, and in turn
high blood sugar levels, vary by racial group (Geiss et al., 2014; Selvin et al., 2011). The effects
of cardiovascular disease were also not accounted for in Study 2. Diabetes is a known risk factor
for cardiovascular disease (Fox et al., 2007; Sarwar et al., 2010). It would be interesting to see if
the relationship between HbA1c and executive function still held true when controlling for health
conditions such as hypertension.
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Implications for Future Research
While there were no significant finding for the association between HbA1c and spatial
navigation performance, there remains interest in studying this relationship. This is particularly
so considering the impact of hippocampal functioning on spatial navigation and the detrimental
effects of high glucose levels on hippocampal structures (Cherbuin et al., 2012; Kerti et al.,
2013; Nedelska et al., 2012). Testing hippocampal volume as a mediator of glucose levels and
spatial navigation would further add to this growing body of research.
Future studies should also focus upon multiple measures of glucoregulation in
combination with an extensive neuropsychological test battery. For instance, testing other factors
such as insulin sensitivity could provide a better picture of glucoregulatory influences on
cognitive status. A recent study has suggested that 1,5-anydroglucitol, a marker of short-term
hyperglycemia, in combination with elevated HbA1c was predictive of dementia risk albeit only
among those with diabetes (Rawlings et al., 2017). Additionally, collecting markers of glucose
levels at multiple time points would be beneficial. It may be that individuals with greater
variability in glucose levels are more prone to impaired cognitive functioning, which has been
evidenced by Ravona-Springer et al. (2012).
With the aging population continuing to grow, it is important to determine ways to keep
older adults cognitively healthy. One such way is by identifying potentially modifiable risk
factors that impact cognitive status. Blood glucose has been tied to cognitive functioning among
individuals with and without diabetes, with higher levels associated with poorer performance
(Ravona-Springer et al., 2012; Seetharaman et al., 2015; Yaffe et al., 2012) and an increased risk
of dementia (Crane et al., 2013). Further, diabetes contributes to an estimated 4.5% of all AD
cases in the United States (Norton, Matthews, Barnes, Yaffe, & Brayne, 2014). Therefore,
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interventions aimed at avoiding hyperglycemic states may be useful in delaying cognitive
decline. More research is necessary, however, to determine the time-point (age) at which high
glucose levels are most detrimental to cognitive health as well as the best metric to assess
glucoregulatory activities.

62

CHAPTER SIX:
CONCLUSION

With aging, changes in cognitive status are anticipated (Salthouse, 2009; Schaie, 2005).
When changes in cognitive status are beyond what is anticipated for age there is cause for
concern. As the aging population continues to grow, there is value in studying ways to delay
cognitive decline and prevent cognitive impairment. It is important first, however, to examine the
mechanisms by which we test interventions to decelerate cognitive aging. One such way is by
testing the ability to translate biological and behavioral observations from animals to human
subjects as was completed with Study 1. There is also value in determining underlying biological
mechanisms which may further exacerbate cognitive changes observed with age as was
completed with Study 2. A number of conclusions can be drawn from the results of both Study 1
and Study 2 which will be discussed further.
Study 1 examined age differences within and between species for MWM performance.
Age differences were more apparent for rats than humans. However, this may be due to the lack
of the young age group for humans. Results also indicated that examining across trial learning
performance may be the best metrics when translating between species. Further, delayed or
probe trials may not be useful in cross species comparison for aged or cognitively impaired
populations. The results of Study 1 has the potential to better inform intervention studies. Future
studies utilizing cross-species comparisons with the MWM should focus on learning across
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trials. More research should be completed examining the translation of other behavioral
paradigms between species as well.
The results of Study 2 indicated that HbA1c had a significant effect on executive
function performance, but not the other measures of cognitive status tested. Further, this
relationship may be moderated by cognitive status (impaired vs non-impaired). While the
absence of results for the HGT are surprising considering the growing body of research
connecting hippocampal atrophy with high blood sugar levels (Cherbuin et al., 2012; Kerti et al.,
2013), it may be that a more complex metric of spatial navigation is needed to fully elucidate the
effect of higher HbA1c. Future studies should also test multiple measures of glucose regulation,
including HbA1c and insulin sensitivity.
The findings from both Study 1 and Study 2 are helpful to research in the field of
cognitive aging. Study 1 provides a detailed evaluation of the translation between animal and
human subjects for a commonly used behavioral paradigm, the MWM. With a better
understanding of the shortcomings using this methodology, interventions targeting cognitive
impairment can be more accurately examined between species. Study 2 provides additional
support for the association between blood glucose levels and executive function. Lowering high
blood glucose levels may be a potential for target for intervention in delaying cognitive decline.
Taken together, this work can help with improving translation and testing interventions as well
as providing further support for a modifiable risk factor of cognitive impairment.
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Table 1
Average MWM Performance for Rats by Age
Young
(n=10)
(SD)

95% CI

M

Old
(n=13)
(SD)

95% CI

MWM Test

M

Distance to Platform (m)

79.00

25.25

[60.94-97.07]

172.30**

73.53

[127.90-216.80]

1.61

Time in Target Quadrant
(%)

39.99

12.56

[31.00-48.97]

24.41*

5.38

[21.16-27.66]

-1.70

Distance to Platform
(m): Logarithmic
Transformation

1.88

0.14

[1.78-1.98]

2.19**

0.21

[2.06-2.32]

1.70

Time in Target Quadrant
(%): Logarithmic
Transformation

1.58

0.14

[1.49-1.68]

1.38**

0.11

[1.31-1.44]

-1.62

Note. *p<.05 as compared to the young group. **p<.001 as compared to the young group.
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Effect Size

Table 2
Mixed Effects Models for Rat MWM Cumulative Distance to the Platform Performance across Trials

No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Trial x Trial
Age Group
Trial x Age Group
Trial x Trial x Age
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

131.76

15.05

<.001

249.84
-111.59
17.52

19.78
17.28
4.14

<.001
<.001
<.001

178.68
-85.56
11.91
125.91
-46.07
9.93

26.05
31.96
6.22
34.64
34.51
8.27

<.001
.001
.059
<.001
.185
.233

3029.25

1569.99

.027

4106.16
0.00a

1545.29

.004

1987.08
0.00 a

919.31

.015

10909.00

1608.51

<.001

5524.87

814.60

<.001

5415.28

798.44

<.001

1415.6
-

3, -

1353.0
62.6*
5, 2

1339.0
14.0*
8, 3

Note. The average performance of four trials per day was calculated and used for comparisons. Distance to the platform was measured
in meters. DF = degrees of freedom. aRandom effect of time was not included in the model. *p<.05.
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Table 3
Mixed Effects Models for Rat MWM Cumulative Distance to the Platform Performance across Trials – Logarithmic Transformation
No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Trial x Trial
Age Group
Trial x Age Group
Trial x Trial x Age
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

1.94

0.06

<.001

2.35
-0.33
0.04

0.07
0.05
0.01

<.001
<.001
<.001

2.25
-0.39
0.04
0.17
0.11
-0.00

0.08
0.07
0.02
0.11
0.10
0.02

<.001
<.001
.018
.094
.265
.941

0.05

0.02

.015

0.06
0.00a

0.02

.002

0.02
0.00 a

0.01

.007

0.12

0.02

<.001

0.05

0.01

<.001

0.04

0.01

<.001

108.7
-

3, -

29.0
79.7*
5, 2

-1.4
30.4*
8, 3

Note. The average performance of four trials per day was calculated and used for comparisons. Distance to the platform was measured
in meters. DF = degrees of freedom. aRandom effect of time was not included in the model. *p<.05.
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Table 4
Participant Characteristics by Age for Study 1
Old-Old
(n=30)

Young-Old
(n=47)
Characteristic

M (SD)

Age

64.94 (4.28)

Sex (female)
Education (years)

%

M (SD)
75.53 (4.46)

68.09
16.00 (2.77)

APOE
e2e2
e2e3
e2e4
e3e3
e3e4
e4e4

%

53.33
15.00 (3.12)

10.64
2.13
72.34
8.51
6.38

23.33
3.33
50.00
23.33

MMSE score

29.13 (0.85)

28.63 (1.27)

GDS Score

1.77 (1.40)

1.47 (1.43)

Note. APOE=apolipoprotein; MMSE=Mini-Mental State Exam; GDS=Geriatric Depression Scale.
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Table 5
Average Hidden Goal Task Performance for Human Subjects by Age
Young-Old
(n=47)
(SD)
95% CI

M

Old-Old
(n=30)
(SD)

Hidden Goal Test

M

95% CI

Effect Size

Complete Data (cm)
Allocentric
Egocentric
Allocentric/Egocentric
Allocentric Delayed

27.96
20.77
21.30
32.04

12.28
7.95
7.50
27.18

[24.35-31.56]
[18.43-23.10]
[19.10-23.50]
[24.65-39.43]

33.37
25.17*
22.23
39.87

17.30
8.61
8.33
31.40

[26.91-39.83]
[21.95-28.38]
[19.12-25.34]
[28.14-51.59]

0.38
0.54
0.12
0.28

Outlier Replaced Data (cm)
Allocentric
Egocentric
Allocentric/Egocentric
Allocentric Delayed†

26.30
20.12
19.75
27.16

10.58
6.53
6.48
17.07

[23.19-29.40]
[18.21-22.04]
[17.85-21.66]
[21.97-32.35]

30.80
21.62
21.74
35.88

15.17
7.68
5.95
28.62

[25.14-36.47]
[18.75-24.49]
[19.52-23.97]
[24.78-46.97]

0.36
0.21
0.32
0.39

Note. *p<.05 when compared to the young-old group. †The outlier replacement data sample size differed from the original sample
(young-old: n=44; old-old: n=28).
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Table 6
Mixed Effects Models for Human Hidden Goal Task Performance with Centered Age: Allocentric Subtest
No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Age
Trial x Age
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

27.98

1.42

<.001

32.81
-1.38

1.87
0.35

<.001
<.001

33.61
-1.49
0.82
-0.11

1.86
0.36
0.28
0.05

<.001
<.001
.003
.039

104.31

25.42

<.001

106.55
0.00a

25.53

<.001

287.83
0.00a

73.82

<.001

394.82

24.36

<.001

383.12

23.64

<.001

380.11

23.45

<.001

5411.4
3, -

5396.0
35.5*
4, 1

5387.1
2.9
6, 2

Note. DF = degrees of freedom. aRandom effect of time was not included in the model. Age was centered at 70 for analytic purposes.
*p<.05.
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Table 7
Mixed Effects Models for Human Hidden Goal Task Performance with Centered Age: Egocentric Subtest
No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Trial x Trial
Age
Trial x Age
Trial x Trial x Age
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

20.51

0.72

<.001

26.62
-3.55
0.36

1.31
0.81
0.11

<.001
<.001
.001

27.19
-3.67
0.37
0.53
-0.10
0.01

1.31
0.82
0.11
0.19
0.12
0.02

<.001
<.001
.001
.006
.409
.720

17.99

6.47

.003

18.82
0.00a

6.40

.002

15.19
0.00a

5.80

.004

167.17

10.31

<.001

157.91

9.74

<.001

157.03

9.68

<.001

4845.1
3, -

4814.4
30.7*
5, 2

4803.7
10.7*
8, 3

Note. DF = degrees of freedom. aRandom effect of time was not included in the model. Age was centered at 70 for analytic purposes.
*p<.05.
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Table 8
Mixed Effects Models for Human Hidden Goal Task Performance with Centered Age: Allocentric/Egocentric Subtest
No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Trial x Trial
Age
Trial x Age
Trial x Trial x Age
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

20.71

0.79

<.001

26.33
-3.32
0.34

1.34
0.80
0.11

<.001
<.001
.002

26.50
-3.33
0.34
0.19
-0.02
-0.00

1.35
0.80
0.11
0.20
0.12
0.02

<.001
<.001
.002
.342
.902
.922

27.93

7.87

<.001

29.11
0.00a

7.89

<.001

28.58
0.00a

7.80

<.001

160.91

9.85

<.001

152.96

9.36

<.001

152.77

9.34

<.001

4905.0
3, -

4878.2
27.2*
5, 2

4876.7
1.5
8, 2

Note. DF = degrees of freedom. aRandom effect of time was not included in the model. Age was centered at 70 for analytic purposes.
*p<.05.
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Table 9
Mixed Effects Models for Human Hidden Goal Task Performance by Age Group: Allocentric Subtest
No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Age Group
Trial x Age Group
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

27.98

1.42

<.001

33.05
-1.43

2.45
0.43

<.001
.001

29.05
-0.80
10.27
-1.63

3.05
0.54
4.89
0.87

<.001
.144
.036
.061

104.31

25.42

<.001

312.61
5.77

78.03
2.46

<.001
.001

287.83
5.21

73.82
2.36

<.001
.014

-0.91
349.37

0.06
23.40

<.001
<.001

-0.90
349.19

.07
23.37

<.001
<.001

394.82

24.36

5411.4
3, -

<.001

5375.9
35.5*
6, 3

Note. DF = degrees of freedom. *p<.05.
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5371.5
4.4
8, 2

Table 10
Mixed Effects Models for Human Hidden Goal Task Performance by Age Group: Egocentric Subtest
No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Trial x Trial
Age Group
Trial x Age Group
Trial x Trial x Age
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

20.51

0.72

<.001

26.62
-3.55
0.36

1.31
0.81
0.11

<.001
<.001
.001

25.82
-3.75
0.40
2.09
0.50
-0.10

1.66
1.03
0.14
2.69
1.67
0.23

<.001
<.001
.005
.438
.762
.650

17.99

6.47

.003

18.82
0.00a

6.40

.002

17.84
0.00a

6.24

.002

167.17

10.31

<.001

157.91

9.74

<.001

157.79

9.73

<.001

4845.1
3, -

4814.4
30.7*
5, 2

Note. DF = degrees of freedom. aRandom effect of time was not included in the model. *p<.05.

75

4812.0
2.4
8, 3

Table 11
Mixed Effects Models for Human Hidden Goal Task Performance by Age Group: Allocentric/Egocentric Subtest
No Growth Model
Estimate
SE
p-value
Fixed Effects
Intercept
Trial
Trial x Trial
Age Group
Trial x Age Group
Trial x Trial x Age
Random Effects
Intercept Variance
Time Variance
Intercept, Time
Covariance
Residual
Model Fit
-2 Log Likelihood
Model Fit Change
DF, Δ DF

Unconditional Growth Model
Estimate
SE
p-value

Conditional Growth Model
Estimate
SE
p-value

20.71

0.79

<.001

26.33
-3.32
0.34

1.34
0.80
0.11

<.001
<.001
.002

26.28
-4.11
0.47
0.14
2.00
-0.33

1.72
1.01
0.14
2.74
1.62
0.22

<.001
<.001
<.001
.958
.218
.146

27.93

7.87

<.001

29.11
0.00a

7.89

<.001

28.74
0.00a

7.81

<.001

160.91

9.85

<.001

152.96

9.36

<.001

152.22

9.32

<.001

4905.0
3, -

4878.2
27.2*
5, 2

Note. DF = degrees of freedom. aRandom effect of time was not included in the model. *p<.05.
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4874.9
3.3
8, 2

Table 12
List of Cognitive Tests Used in Study 1 and Study 2

Domain

Test

Measure

Scoring

Verbal Memory
RAVLT Total
RAVLT Delay

Words recalled in trials 1-5
Words recalled after 30 min delay

Max score 75
Max score 15

ROCF Immediate Recall

Ability to reproduce a figure drawing from
memory immediately following exposure

Max score 36

Digit Span Forward
Digit Span Backward

Number of digits correctly recalled in order
Number of digits correctly recalled in reverse
order
Time to connect numbers in ascending order

Max score 16
Max score 14

ROCF Complex Copy

Ability to reproduce a figure drawing from
memory 30 minutes after exposure

Max score 36

Trail Making Test B

Time to connect numbers/letters in ascending
order
Number of words recited beginning with “N,
K, P”

Max time 500 sec

Nonverbal Memory

Working Memory

Trail Making Test A

Max time 150 sec

Visuospatial Skills

Executive Function

COWAT Total

Spatial Navigation
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60 sec to complete
per letter

HGT Real Space
Allocentric/egocentric
Allocentric
Egocentric
Allocentric Delay

HGT Virtual
Allocentric/egocentric
Allocentric
Egocentric
Allocentric Delay

Locating the hidden goal based on start
position and visual cues
Locating the hidden goal based upon visual
cues
Locating the hidden goal based upon start
position
Locating the hidden goal following 30 minute
delay

Distance error (cm)

Locating the hidden goal based on start
position and visual cues
Locating the hidden goal based upon visual
cues
Locating the hidden goal based upon start
position
Locating the hidden goal following 30 minute
delay

Distance error
(pixels)
Distance error
(pixels)
Distance error
(pixels)
Distance error
(pixels)

Distance error (cm)
Distance error (cm)
Distance error (cm)

Note. RAVLT=Rey Auditory Verbal Learning Test; ROCF=Rey-Osterreith Complex Figure; COWAT=Controlled Oral Word
Association Test; HGT=Hidden Goal Task.
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Table 13
Study 2 Participant Characteristics by Cognitive Status

Characteristic

Cognitively Healthy
(n=24)
M (SD)
%

Subjective
Cognitive Decline
(n=39)
M (SD)
%

Mild Cognitive
Impairment
(n=55)
M (SD)
%

Alzheimer’s disease
(n=15)
M (SD)
%

Age

68.83 (6.66)*†

67.72 (6.38)*†

74.91 (7.22)

74.27 (6.39)

Sex (female)
Education (years)

75.00
16.46 (2.48)

APOE
e2e2
e2e3
e2e4
e3e3
e3e4
e4e4
MMSE score

61.54
14.67 (2.78)

16.67
4.17
62.50
16.67
29.42 (0.78)*†

56.36
14.35 (2.98)**

7.69
2.56
69.23
12.82
7.69
28.72 (1.05)*†

60.00
13.67 (3.02)**

9.09
5.45
40.00
38.18
7.27
26.76 (2.20)†

40.00
53.33
6.67
20.60 (2.87)*

GDS score

1.00 (1.18)

2.05 (1.43)**

2.56 (1.38)**

2.33 (1.23)**

HbA1c (%)

5.97 (0.54)

6.00 (0.70)

5.88 (0.53)

6.12 (0.48)

Diabetes
4.17
23.08
9.09
33.33
Note. APOE=apolipoprotein; MMSE=Mini-Mental State Exam; HbA1c=glycosylated hemoglobin; GDS=Geriatric Depression Scale.
*p<.05 as compared to the mild cognitive impairment group. †p<.05 as compared to the AD group. **p<.05 as compared to the
cognitively healthy group.
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Table 14
Correlations between Demographics, Biomarkers, and Neuropsychological Test Performance for Complete Data Sample
Measure

Age

Gender

Education

GDS

APOE

Cog Impair

Diabetes

HbA1c

Verbal Memory

-.482***

.093

.224*

-.294*

-.319**

-.850***

.073

.002

Nonverbal Memory

-.481***

-.056

.247*

-.327**

-.278**

-.641***

.092

.055

Working Memory

-.320**

-.016

.223*

-.183*

.003

-.487***

-.122

-.127

Visuospatial Skills†

-.291*

.056

.126

-.235*

-.010

-.455***

-.015

.020

Executive Function

-.375***

-.032

.286*

-.291*

.040

-.493***

-.018

-.195*

HGT Real Space Allo/Ego

.231*

.139

-.141

.250*

.078

.455***

-.016

.031

HGT Real Space Allocentric

.297**

.085

-.196*

.156

.229*

.510***

-.011

.061

HGT Real Space Egocentric

.320**

.062

-.117

.154

.197*

.423***

-.064

.018

HGT Real Space Delay

.231*

.064

-.121

.142

.272*

.422***

-.028

.038

HGT Virtual Allo/Ego

.283*

.116

-.167

.218*

.093

.364***

-.027

.046

HGT Virtual Allocentric

.311**

.096

-.171

.218*

.213*

.493***

-.025

.043

HGT Virtual Egocentric

.392***

.103

-.181

.261*

.233*

.494***

-.063

-.002

HGT Virtual Delay

.214*

.065

-.135

.194*

.247*

.466***

.026

.120

Note. Cog Impair variable reflects cognitive status as impaired vs non-impaired. Dependent variables were converted to z-scores. GDS=Geriatric
Depression Scale; APOE=apolipoprotein; HbA1c=glycosylated hemoglobin; HGT=Hidden Goal Task. *p<.05. **p<.001. ***p<.0001.
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Table 15
Correlations between Demographics, Biomarkers, and Neuropsychological Test Performance for Multiple Imputation Sample
Measure

Age

Gender

Education

GDS

APOE

Cog Impair

Diabetes

HbA1c

Verbal Memory

-.455***

.092

.274*

-.240*

-.306**

-.835***

-.015

-.038

Nonverbal Memory

-.475***

-.028

.284**

-.284**

-.279*

-.685***

.019

.027

Working Memory

-.355***

.058

.242*

-.171*

.082

-.493***

-.189*

-.139

Visuospatial Skills

-.276*

.029

.159

-.170

-.150

-.475***

-.174*

-.003

Executive Function

-.402***

.057

.313**

-.252*

.086

-.529***

-.110

-.200*

HGT Real Space Allo/Ego

.251*

.127

-.154

.189*

.104

.471***

-.012

-.030

HGT Real Space Allocentric

.260*

.036

-.244*

.086

.240*

.538***

.065

.072

HGT Real Space Egocentric

.271*

.096

-.212*

.142

.186*

.453***

.009

.015

HGT Real Space Delay

.180*

.043

-.188*

.073

.266*

.458***

.062

.041

HGT Virtual Allo/Ego

.291**

.073

-.173*

.137

.200*

.437***

.048

-.020

HGT Virtual Allocentric

.297**

.039

-.208*

.151

.212*

.539***

.067

.065

HGT Virtual Egocentric

.364***

.123

-.244*

.255*

.231*

.524***

-.020

-.007

HGT Virtual Delay

.187*

.104

-.209*

.166

.236*

.471***

.031

.094

Note. Cog Impair variable reflects cognitive status as impaired vs non-impaired. Dependent variables were converted to z-scores. HbA1c was log
transformed. GDS=Geriatric Depression Scale; APOE=apolipoprotein; HbA1c=glycosylated hemoglobin; HGT=Hidden Goal Task. *p<.05.
**p<.001. ***p<.0001.

81

Table 16
Regression Models for HbA1c and Executive Function Performance with Cognitive Impairment

Model 1
Variable
Intercept
Age
Gender
Education
Depression
Diabetes
Cognitive Impairment
HbA1c
HbA1c x Cog Impair
R2
Δ R2
ΔF

B
1.80
-0.04
0.00
0.06
-0.11
-0.13

SE
0.87
0.01
0.15
0.02
0.05
0.20

β
-0.31
0.00
0.22
-0.19
-0.06

Model 2
pvalue
.041
<.001
.980
.013
.030
.505

B
5.41
-0.02
-0.01
0.04
-0.07
0.28
-0.61
-2.48

.24
-

SE
1.76
0.01
0.14
0.02
0.05
0.24
0.15
0.92

β
-0.16
-0.01
0.16
-0.13
0.12
-0.37
-0.28

.38
.14
11.91

Model 3
pvalue
.003
.074
.935
.055
.137
.261
<.001
.008

<.001

B
1.05
-0.02
-0.03
0.04
-0.05
0.28
-0.64
-1.39
-2.97

SE
0.81
0.01
0.14
0.02
0.05
0.24
0.14
1.05
1.44

-0.13
-0.01
0.12
-0.07
0.10
-0.32
-0.13
-0.14

pvalue
.192
.064
.831
.075
.314
.243
<.001
.188
.041

.40
.02
4.27

.041

β

Note. Cognitive Impairment variable reflects cognitive status as impaired vs non-impaired. HbA1c was log transformed. HbA1c=glycosylated
hemoglobin.
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Table 17
Regression Models for HbA1c and Executive Function Performance with Cognitive Group

Model 1
Variable
Intercept
Age
Gender
Education
Depression
Diabetes
HbA1c
Cognitive Group
vs aMCI
vs AD
HbA1c x Cog Group
vs aMCI
vs AD
R2
Δ R2
ΔF

B
1.80
-0.04
0.00
0.06
-0.11
-0.13

SE
0.87
0.01
0.15
0.02
0.05
0.20

β
-0.31
0.00
0.22
-0.19
-0.06

Model 2
pvalue
.041
<.001
.980
.013
.030
.505

B
5.12
-0.02
-0.02
0.05
-0.06
0.26
-2.30

SE
1.72
0.01
0.14
0.02
0.05
0.24
0.90

-0.52
-1.19

0.15
0.27

.24
-

Model 3

-0.17
-0.10
0.17
-0.11
0.11
-0.26

pvalue
.004
.052
.891
.034
.185
.280
.012

B
1.06
-0.02
-0.03
0.04
-0.04
0.27
-1.32

SE
0.79
0.01
0.14
0.02
0.05
0.24
1.03

-0.14
-0.02
0.13
-0.06
0.09
-0.12

pvalue
.183
.048
.825
.051
.377
.261
.204

-0.31
-0.35

<.001
<.001

-0.55
-1.17

0.15
0.28

-0.27
-0.28

<.001
<.001

-2.69
-3.54

1.43
5.55

-0.25
-0.33

.063
.525

.43
.02
1.87

.160

β

.41
.17
10.42

<.001

β

Note. HbA1c was log transformed. HbA1c=glycosylated hemoglobin; aMCI=amnestic mild cognitive impairment; AD=Alzheimer’s disease.
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Table 18
Regression Models for HbA1c and Executive Function Performance with Cognitive Impairment Imputation

Model 1
Variable
Intercept
Age
Gender
Education
Depression
Diabetes
Cognitive Impairment
HbA1c
HbA1c x Cog Impair
R2
Δ R2
ΔF

B
1.59
-0.04
0.15
0.08
-0.10
-0.30

SE
0.78
0.01
0.14
0.02
0.05
0.18

β
-0.27
0.07
0.23
-0.14
-0.11

Model 2
pvalue
.041
<.001
.289
<.001
.038
.090

B
4.25
-0.02
0.10
0.06
-0.05
0.02
-0.64
-1.83

.23
-

SE
1.62
0.01
0.13
0.02
0.04
0.22
0.13
0.85

β
-0.15
0.05
0.17
-0.08
0.01
-0.32
-0.17

.34
.11
2.86

Model 3
pvalue
.009
.027
.424
.006
.232
.913
<.001
.029

<.05

B
0.79
-0.02
0.07
0.05
-0.03
0.06
-0.66
-2.13
-2.81

SE
0.70
0.01
0.13
0.02
0.04
0.22
0.13
0.85
2.97

-0.15
0.04
0.15
-0.04
0.02
-0.33
-0.19
-0.13

pvalue
.255
.019
.563
.012
.490
.777
<.001
.012
.029

.35
.01
0.23

>.05

Β

Note. Cognitive Impairment variable reflects cognitive status as impaired vs non-impaired. HbA1c was log transformed. HbA1c=glycosylated
hemoglobin.
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Table 19
Regression Models for HbA1c and Executive Function Performance Imputation Sample with Cognitive Group Imputation

Model 1
Variable
Intercept
Age
Gender
Education
Depression
Diabetes
HbA1c
Cognitive Group
vs aMCI
vs AD
HbA1c x Cog Group
vs aMCI
vs AD
R2
Δ R2
ΔF

B
1.59
-0.04
0.15
0.08
-0.10
-0.30

SE
0.78
0.01
0.14
0.02
0.05
0.18

β
-0.27
0.07
0.23
-0.14
-0.11

Model 2
pvalue
.041
<.001
.289
<.001
.038
.090

B
4.38
-0.02
0.12
0.05
-0.06
0.15
-1.90

SE
1.53
0.01
0.12
0.02
0.04
0.21
0.81

-0.48
-1.22

0.13
0.19

.23

Model 3

-0.14
0.06
0.16
-0.08
0.05
-0.17

pvalue
.004
.018
.329
.007
.166
.464
.018

B
0.64
-0.03
0.10
0.05
-0.04
0.17
-2.39

SE
0.67
0.01
0.12
0.02
0.04
0.21
1.06

-0.15
0.05
0.15
-0.06
0.06
-0.22

pvalue
.341
.014
.431
.012
.342
.427
.024

-0.24
-0.39

<.001
<.001

-0.50
-1.20

0.13
0.20

-0.25
-0.38

<.001
<.001

-2.17
-1.91

1.32
2.33

-0.09
-0.06

.102
.414

.40
.01
0.21

>.05

β

.39
.16
3.90

<.001

β

Note. HbA1c was log transformed. HbA1c=glycosylated hemoglobin; aMCI=amnestic mild cognitive impairment; AD=Alzheimer’s disease.
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Figure 1. Morris water maze performance across trials: Young rats. Trials were collapsed across training days.
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Figure 2. Morris water maze performance across trials: Aged rats. Trials were collapsed across training days.
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Figure 3. Morris water maze performance across days: Raw data. Trials were collapsed across training days.
Young animals were 3 months of age. Old animals were 20 months of age.
.
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Figure 4. Average performance across trials: Allocentric subtest. Age was evaluated in two
ways: (A) Centered at 70 for the continuous measure and (B) by age groups including young-old
(53-70) and old-old (71-85) participants.
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Figure 5. Average performance across trials: Egocentric subtest. Age was evaluated in two ways:
(A) Centered at 70 for the continuous measure and (B) by age groups including young-old (5370) and old-old (71-85) participants
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Figure 6. Average performance across trials: Allocentric/Egocentric subtest. Age was evaluated
in two ways: (A) Centered at 70 for the continuous measure and (B) by age groups including
young-old (53-70) and old-old (71-85) participants.
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Figure 7. Simple slopes analyses for executive function by cognitive impairment status. Non-impaired reflects individuals classified as cognitively
healthy or subjective cognitive decline. Impaired reflects individuals classified as having amnestic mild cognitive impairment or
Alzheimer’s disease. A significant relationship was observed for HbA1c and executive function for the impaired group.
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Figure 8. Simple slopes analyses for executive function by cognitive group. CH=cognitively healthy; SCD=subjective cognitive decline;
aMCI=amnestic mild cognitive impairment; AD=Alzheimer’s disease. A significant relationship was observed for HbA1c and executive
function for the aMCI group.
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